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ABSTRACT 
 
ROBERT AUBREY FULCHER:  Effectors of Haemophilus ducreyi Pathogenesis 
(Under the direction of Thomas H. Kawula) 
 
Chancroid is a sexually-transmitted infection (STI) prevalent in impoverished 
regions of the developing world.  Caused by the gram-negative bacterium Haemophilus 
ducreyi (Hd), an obligate human pathogen, chancroid is characterized by purulent genital 
skin ulceration and increased risk of acquiring other STI including HIV.  Chancroid is 
treatable with antibiotic therapy but does not elicit protective immunity to subsequent Hd 
infection.  To further explore Hd-host interactions, we examined two targets:  an Hd 
surface protein targeted by the host’s modest anti-Hd humoral response, and a secreted 
Hd toxin implicated in pathogenesis and immune modulation. 
We identified Hd outer-membrane protein NcaA as an Oca-family bacterial 
adhesin.  We demonstrated that NcaA mediated Hd binding to the host skin protein 
collagen.  Furthermore, we found that NcaA was essential for virulence in human and 
swine models of chancroid, suggesting an important link between skin colonization and 
survival in the host.   
Most Hd isolates secrete cytolethal distending toxin (CDT), a trimeric complex 
that intoxicates many eukaryotic cell types, including some found in skin (fibroblasts, 
keratinocytes) and others relevant to immunity (macrophages, lymphocytes).  We 
therefore investigated CDT as a contributor to Hd pathogenesis and host immune 
iv 
 
modulation.  Two independent Hd CDT-deletion (ΔCDT) mutants were attenuated in 
the swine chancroid model, but neither could be complemented, showing that CDT 
deletion selected for cryptic attenuating mutations.   These results support but cannot 
confirm the importance of CDT to Hd pathogenesis.  Additionally, pigs inoculated twice 
with ΔCDT Hd were as susceptible to wild type Hd challenge as pigs previously 
inoculated twice with CDT+ Hd.  Though this finding did not illustrate CDT-mediated 
immune alteration, ΔCDT strains may not persist sufficiently in vivo to elicit immunity 
regardless of any CDT effect.   
Following published findings attributing CDT toxicity to nuclease activity of 
subunit CdtB, we generated an Hd mutant with minimal amino acid variations mapping 
to the CdtB active site, attempting to circumvent compensatory mutation.  This mutant 
retained CDT toxicity; furthermore, purified mutant CdtB protein retained in vitro 
nuclease activity.  Further studies are warranted to address the importance of CdtB 
nuclease activity and CDT toxicity to Hd host-pathogen interaction. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
Chancroid is a sexually transmitted disease that is largely unrecognized by the 
American public, and rarely seen by health professionals outside developing countries.  It 
is caused by the gram-negative bacterium Haemophilus ducreyi, a fastidious obligate 
human pathogen.  Over the last few years, only a handful of chancroid cases have been 
reported in the United States.  Despite its relative scarcity in developed nations, chancroid 
is prevalent in many relatively impoverished areas of the world.  These regions also suffer 
from poor public health care and limited access to antibiotic therapies, which are still very 
effective against chancroid.  Chancroid patients are not afforded protective immunity 
following infection.  Those repeatedly exposed to H. ducreyi can contract the disease 
multiple times.  Because the transmission rate is high, most chancroid patients in 
endemic areas have a high probability of being infected more than once.  The most 
troubling health burden of chancroid comes not from the pathology that it causes, but 
from the increased susceptibility of its host to infection with other sexually transmitted 
infections (STI), many of which are neither as benign nor as treatable.  For these reasons, 
it is important to understand the means by which chancroid causes disease, modulates 
immunity, and facilitates acquisition of other pathogens. 
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History of chancroid 
 Chancroid is a member of the family of genital ulcer diseases (GUD) including 
syphilis, herpes and donovanosis, among others.  Chancroid was first recognized as a 
distinct GUD in 1852, when French dermatologist Leon Bassereau distinguished the 
chancroid ulcer from the similar chancre seen in syphilis (11).  Although Bassereau did 
not identify the causative agent or agent(s), making a distinction between syphilis and 
chancroid lesions was a testament to his skill; even today, it is thought that many cases of 
chancroid are misdiagnosed and improperly reported as other GUD such as syphilis or 
herpes (78).  Over three decades later, French research assistant Auguste Ducrey began a 
detailed study of the ulcus molle, or “soft chancre” associated with chancroid.  Though he 
was unable to culture the agent on laboratory media, he showed that chancroid lesions 
could be serially passaged along the forearm skin of patients by autoinoculation with 
exudate from the primary ulcer (25).  After several passages, Ducrey isolated the specific 
agent:  a “streptobacillary rod with a clumping or chaining morphology” (26).   
Some speculation remains as to which scientist or scientists first isolated 
“Ducrey’s bacillus”, and this controversy has been reviewed in detail (4, 33).   Bezancon, 
however, published verification of Koch’s postulates by isolating the bacillus from a 
chancroid lesion, obtaining a pure culture on blood agar, inoculating healthy subjects 
with this culture, and re-isolating the causative agent from the experimental lesion (15).  
Ducrey’s bacillus was later classified in the genus Haemophilus based on its gram-negative 
phenotype, its coccobacillary morphology and its metabolic requirement for factors X 
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(hemin) and V (nicotinamide adenine dinucleotide) (4).  Various studies involving DNA 
homology (18) and 16S ribosomal RNA sequencing (21) have since placed H. ducreyi 
within the family Pasteurellaceae, distinct from the main grouping of true Haemophilus 
species.  The closest relatives of H. ducreyi reside within the Actinobacillus and Pasteurella 
genera (23).   
 
Chancroid pathology in the human host 
 Haemophilus ducreyi is an obligate human pathogen, occupying no other known 
environmental or animal vector niche (57).  It is transmitted and acquired solely by direct 
physical contact with H. ducreyi bacteria shed from an infected individual via the 
chancroid lesion.  H. ducreyi enters a new host through microscopic tears in the 
epidermis, such as those sustained during sexual intercourse.  As few as 10 to 100 bacteria 
are thought to be required to initiate infection, as determined in an experimental human 
chancroid model (81, 83).  Within 4 to 10 days a raised red papule forms at the site of 
entry, and over the next few days develops into a pustule.  Most people are unaware of 
infection through these first stages, but eventually the pustule ruptures to form an acutely 
painful chancroid ulcer, prompting most chancroid patients to seek medical intervention. 
Lesion pathology associated with H. ducreyi infection has been well documented 
(4, 33, 57, 58, 81), and is summarized here.  The typical chancroid ulcer is irregular in 
shape, bordered by a reddened edge but with limited erythema of surrounding skin 
(Figure 1.1A).  The floor of the ulcer has a rough granular appearance, and bleeds easily 
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when disturbed or abraded.  Chancroid ulcers exude copious purulent material and are 
highly vascularized, bleeding easily upon abrasion.  Men most often develop lesions on 
the foreskin, glans, or distal shaft of the penis, whereas lesions in women develop on the 
external genitalia.  Ulcers can also occur on the vaginal wall or cervix, but these lesions 
are typically not painful and thus often remain untreated.  Like the subjects of Ducrey’s 
early research, naturally infected patients may generate secondary lesions on their hands 
or forearms by autoinoculation of bacteria from the primary lesion.  This peculiarity of 
chancroid demonstrates that protective immunity is not elicited by H. ducreyi infection.   
If left untreated, a given chancroid lesion will resolve within one to two months 
following ulcer formation.  H. ducreyi does not persist within the body after resolution, 
nor does it cause systemic infection, though in some instances infection may ascend to 
the draining inguinal lymph node, leading to an intense inflammatory response that 
produces an inguinal bubo.  This complication occurs more often in men than in women, 
and without drainage by aspiration or incision, buboes can rupture (Figure 1.1B).  
Interestingly, aspirate from chancroid-associated buboes contains relatively few H. 
ducreyi bacteria as compared to purulent matter isolated from the primary lesion.  In 
extraordinary cases, prolonged untreated cases of chancroid in men can produce 
anatomical damage requiring circumcision or surgical reconstruction.    
 Chancroid pathology is largely mediated by the host’s immune response to H. 
ducreyi.  Histological examination of the chancroid ulcer shows a profound cellular 
infiltrate chiefly populated by polymorphonuclear leukocytes (PMN).  The primary role 
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of PMN in chancroid is to generate reactive oxygen and nitrogen species in an attempt to 
keep H. ducreyi in check; this sustained influx of PMN to the lesion site produces the 
characteristic papule-pustule-ulcer progression.  H. ducreyi is especially effective at 
inducing of IL-8 expression by skin cells (96); IL-8 is a chemoattractant for both PMN 
and T lymphocytes (61) which are also prevalent within the chancroid lesion.  H. ducreyi 
appears to withstand the oxidative burst and, in fact, replicates within the base of the 
lesion.  The presence of T lymphocytes (predominantly CD8+) and macrophages within 
the lesion along with elevated TNFα, IL-8, and IFNγ (46) have led researchers to describe 
the anti-H. ducreyi response as a delayed-type hypersensitivity (DTH) reaction (64).  
DTH reactions are recall responses requiring an initial priming exposure to the target 
antigen(s); it is not known whether cross-reactivity to other related bacterial antigens 
potentiates a bonafide DTH response against H. ducreyi. 
Despite the ferocity of the innate immune response to H. ducreyi infection, the 
adaptive immune response to H. ducreyi appears much less effective.  Because H. ducreyi 
is an extracellular pathogen (12-14), durable immunity would likely involve a humoral 
response.  People who have ulcerated lesions for less than one week may not seroconvert, 
but people with ulcers of 8-day duration or higher mount an H. ducreyi-specific antibody 
(IgM, IgG and IgA) response that increases during infection and persists (predominantly 
IgG) for at least 18 months afterward (6, 69, 72).  However, even people with measurable 
anti-H. ducreyi antibody titers are not immune, as evidenced by susceptibility to repeated 
autoinoculation used in early chancroid studies identifying chancroid (25) as well as in 
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early chancroid diagnosis (37).  It is unclear whether the low efficacy of humoral 
immunity results from low immunogenicity of the bacterium, preferential generation of 
antibodies against ineffective H. ducreyi targets, or the disproportionately large 
contribution of the innate immune response to the overall chancroid syndrome.  It is 
possible that H. ducreyi has developed mechanisms to actively modulate host immunity, 
amplifying the cellular response at the expense of the humoral response.   
In the United States, herpes is the most common GUD, followed by syphilis, then 
chancroid and other bacterial GUD.  Direct diagnosis of chancroid is problematic; no 
FDA-approved nucleic acid test currently exists for H. ducreyi, and culture is difficult 
because the bacterium does not survive well in routine transport media and must be 
directly plated onto enriched media (50, 94).  Detection frequency from ulcer swab 
cultures is approximately 40% (50). Though some labs have developed certified in-house 
PCR-based H. ducreyi diagnostics, chancroid is most often diagnosed by excluding 
syphilis and herpes.  A patient presenting ulcerative genital lesions should be tested for 
syphilis by dark-field microscopy (to detect T. pallidum spirochetes in lesion exudate) 
and for herpes simplex virus (HSV) by culture or serology.  Negative results for these tests 
yield a presumptive diagnosis of chancroid.  Accompanying inguinal lymphadenopathy is 
also highly suggestive of H. ducreyi infection.  Further complicating diagnosis is the fact 
that many GUD patients are simultaneously infected with more than one of these 
pathogens (94). 
 
7 
 
Chancroid and public health 
 Chancroid is a rare disease in industrialized nations, far eclipsed by herpes as the 
most common GUD (58).  Surveillance data from 2004 indicate that only 17 chancroid 
cases occurred in the United States (19), though difficulty in culturing H. ducreyi and its 
potential misdiagnosis as syphilis likely contribute to a lower apparent frequency (78).  
Limited outbreaks within the United States have occurred within the past two decades, 
and have been associated with communities in which drug use and HIV are common (24, 
55).   
Chancroid is most prevalent in the developing world, primarily impoverished 
areas of Southeast Asia, Sub-Saharan Africa, South America and the Caribbean (58, 59, 
71).  In these countries, endemic chancroid accounts for the majority of GUD cases (58).  
HIV is also common in these areas, and shares an “epidemiological synergy” with GUD 
(90).  HIV-positive individuals with GUD more efficiently transmit HIV to their sexual 
partners, and GUD in HIV-negative individuals can increase their risk of HIV 
seroconversion by up to 18-fold upon sexual contact with an infected partner (74).  The 
presence of CD4+ T lymphocytes within chancroid ulcers provides a potential ready target 
for HIV acquisition (83) and supports other findings suggesting that the cooperative 
interaction between chancroid and HIV may be greater than that in other GUD (52).  
HIV also increases the potential for H. ducreyi transmission, producing more persistent 
chancroid lesions (45, 68).  With a transmission rate approaching 70 percent (66), the 
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important role of chancroid in the global dissemination of HIV clearly warrants efforts to 
control or eradicate H. ducreyi.   
Antibiotic therapy remains effective against H. ducreyi infection.  Current 
recommended therapy consists of single-dose azithromycin (1 g) or ceftriaxone (250 mg 
IM), or a three- to seven-day course of ciprofloxacin or erythromycin, although some 
isolates resistant to the latter two drugs are emerging.  Single-dose therapies are 
particularly beneficial in ensuring patient compliance, however these drugs are relatively 
expensive and are not often dispensed in areas where chancroid is most common (94).  In 
addition, chancroid in HIV-patients is often poorly responsive to antibiotic treatment 
(45, 68). 
The primary obstacles to chancroid eradication are poor access to health care and 
the synergistic relationship between chancroid and HIV.  Antibiotic treatment failure is 
much more common in HIV-positive chancroid patients, whose lesions may be more 
severe and persistent than those in immunocompetent individuals (52, 68).   Though 
some laboratory animal model studies have generated hopeful H. ducreyi vaccine 
candidates, no vaccine is currently available.  As an obligate human pathogen, it is 
conceivable that with aggressive implementation of such a vaccine, as well as improved 
health care and education, chancroid eradication may be feasible.   
 
Chancroid model systems 
 Model systems have been developed to better understand the means by which H. 
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ducreyi causes disease.  Cell lines derived from skin keratinocytes (HaCaT) and 
fibroblasts (Hs27), as well as the more common HeLa and COS-7 lines have been 
employed to study virulence of H. ducreyi as well as purified components thereof.  More 
complex stratified co-culture systems have also been used to study H. ducreyi in an 
environment that more closely mimics the stratified structure of skin (39, 96).  Although 
focused and convenient, in vitro studies lack the ability to assess pathogenesis in the 
context of an intact host response.  To better characterize H. ducreyi pathogenesis, several 
animal models of chancroid have been developed.  In both in vitro and in vivo model 
systems, work with various isolates and genetically-modified strains of H. ducreyi has 
revealed much about the molecular pathogenesis of chancroid. 
The rabbit model is probably the most long-standing animal model for chancroid.  
Ducrey attempted unsuccessfully to culture H. ducreyi by intradermal injection into 
rabbits (25, 26) but a temperature-dependent rabbit model later refined by Purcell et al. 
(67) produced a more consistent and representative experimental chancroid lesion.  In 
this model, rabbits are housed at 15-17°C to provide a more suitable in vivo growth 
temperature for H. ducreyi, which grows optimally at approximately 33°C.  The number 
of H. ducreyi bacteria required to elicit a lesion in the rabbit model is relatively high, and 
after naïve rabbits are inoculated with H. ducreyi (34) or with purified H. ducreyi 
lipooligosaccharide or pilin (22), they mount a vigorous antibody response that protects 
from subsequent infection.  While relatively inexpensive and useful for identifying 
virulence factors that have a profound effect on initiation of H. ducreyi infection (82, 88, 
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91), the facile development of immunity to H. ducreyi in the rabbit model contrasts 
sharply with natural chancroid in humans, making this model less suitable for 
characterizing the immune response directed at H. ducreyi. 
 A primate model of chancroid was developed by Totten et al. (87) to approximate 
more closely the human host environment to study H. ducreyi pathogenesis.  This model 
provided the unique opportunity to inoculate genital skin of both male and female 
macaques to more accurately study H. ducreyi infection within the context of the 
anatomical site of naturally-acquired chancroid.  Lesion pathology and immune response 
in macaques appeared to be congruent with that in humans, including the formation of 
ulcerated lesions harboring viable H. ducreyi over the span of three weeks, and the 
induction of inguinal lymphadenopathy in a subset of the male macaques.  However, 
females were not susceptible to H. ducreyi infection (87).  The primary disadvantage of 
this model is the extremely high cost of using primates as research animal subjects. 
 Spinola et al. developed a human challenge model of chancroid, citing the obvious 
advantage of studying H. ducreyi infection within its natural host.  Healthy volunteers are 
inoculated on the upper arm with a standard allergy test applicator, and disease 
progression is monitored using a variety of measurements including lesion formation 
frequency, histopathology, culture of viable organisms from lesions, and comparison 
between mutant and parental H. ducreyi strains (83).  The course of lesion development 
closely mimics the natural disease and volunteers do not become immune to infection, 
even after second inoculation (9).  Pustule formation is a mandatory endpoint for 
11 
 
experimental infection due to the discomfort involved, so lesions at the late pustular or 
ulcerative stages cannot be modeled in humans.  This restriction may preclude 
development of an immune response similar to that seen in natural infection.  
Furthermore, recombinant H. ducreyi strains containing mobile antibiotic resistance 
elements may not be tested in the human model.  Despite these restrictions, the human 
model is an invaluable source of information regarding the contributions of many H. 
ducreyi gene products to chancroid pathogenesis (7, 8, 13, 32, 65, 85, 86). 
 The swine model of chancroid capitalizes on the anatomical and physiological 
similarities between pigs and humans.  First described by Hobbs et al. (40) this 
experimental approach employs young pigs inoculated with H. ducreyi in a manner 
similar to that used in the human model.  This model uses the dorsal aspect of the pig ear, 
where skin thickness closely approximates that of human thin skin, and the skin 
temperature is near the ideal of 34-35°C.  Lesion formation is somewhat accelerated 
relative to humans, but the histopathology of the resulting ulcers is very similar to natural 
chancroid.  Each inoculation site can be analyzed as an independent lesion, as was shown 
in the human model (10), and the surface area of the pig ear allows simultaneous 
inoculation of multiple sites.  Thus, the pig model produces a large amount of data from 
each animal.  Furthermore, like humans, pigs do not become immune following single 
infection, remaining susceptible for multiple rounds of inoculation.  Studies of immune 
response in this model are somewhat hampered by the fact that swine immunology is less 
well-defined than that of the canonical mouse or human.  Furthermore, the pig model 
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system is somewhat sensitive to high temperature, and pigs must be housed at an ambient 
temperature no greater than 68°F.  Overall, we have found the swine model to be a 
workable compromise between the host species parity of the human model and the ability 
to allow lesions to progress to resolution, if warranted. 
 
The arsenal of Haemophilus ducreyi 
 In order to survive within the human host, H. ducreyi employs a range of 
molecular tools.  Most of these virulence factors address primary concerns of a bacterial 
pathogen:  acquisition of nutrients, adherence to host tissues, and evasion of host 
defenses.  Over the past several decades, with the help of many collaborative efforts, much 
knowledge has been gained regarding these virulence determinants in H. ducreyi.  To 
date, eight gene products or loci have been identified (8, 20, 31, 41, 42, 48, 82, 88) that are 
indispensable for H. ducreyi infection in one or more experimental chancroid models, 
including one which will be discussed later in Chapter 3.  Some examples of these 
virulence factors are summarized below.   
 
Nutrient acquisition 
 As an obligate human pathogen, H. ducreyi is keenly adapted to its natural habitat 
within host skin tissue.  The detriment of this adaptation is that H. ducreyi requires a very 
rigid set of parameters for growth.  Iron acquisition is of particular importance; a primate 
model study showed that providing macaques with supplemental iron reduced the 
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number of H. ducreyi bacteria required to form chancroid lesions (84).  As a 
predominantly extracellular pathogen, H. ducreyi must live within a host environment 
that is practically devoid of non-sequestered iron.  H. ducreyi has evolved the ability to 
acquire iron from a variety of heme-containing sources within the host, such as hemin, 
hemoglobin and catalase (49).  Elkins et al. characterized the hemoglobin-binding protein 
HgbA (27, 28), which mediates TonB-dependent (30) iron scavenging from heme sources 
in the host.  Not only is HgbA expression required for H. ducreyi growth in humans (8), 
but immunization of pigs with purified HgbA produced a humoral response that is highly 
bactericidal in vitro and completely protected immunized pigs against H. ducreyi 
challenge (2).  This result demonstrates the importance of iron acquisition to H. ducreyi 
survival in vivo, and shows that HgbA is a very promising immunogen for incorporation 
into a chancroid vaccine. 
 
Adherence to host tissues 
 Some Actinobacillus species carry genes encoding fimbria-like proteins that enable 
adherence to a variety of inert and biological surfaces (43, 44).  The flp operon is a 
homologous multigene cluster found in H. ducreyi that is required for the formation of 
microcolonies in vitro (60).  Because adherence to host tissue is often an important 
preliminary step in establishing bacterial infection, strains of H. ducreyi unable to 
manufacture Flp proteins were assayed for virulence.  Excision of  flp1 and flp2 (Flp 
structural subunit genes) had no impact on H. ducreyi virulence in the rabbit chancroid 
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model (60), but inactivation of tadA, a central flp locus gene and putative energizer of the 
flp system, resulted in an attenuation in the human challenge model (82).  To date, the 
flp1 flp2 mutant has not been tested in humans, and it is not known whether the loss of 
TadA or the polar effect of the tadA mutation on downstream genes is responsible for the 
attenuated phenotype of this mutant (60). 
 As part of the innate immune system, complement molecules present in normal 
non-immune serum can attach to certain conserved bacterial structures, activating the 
antibacterial complement cascade in the absence of pathogen-specific antibodies, known 
as the “alternative pathway” of complement fixation (70).  H. ducreyi proteins DsrA and 
DltA are involved in H. ducreyi serum resistance, preventing initiation of the alternative 
pathway against H. ducreyi and thereby deflecting one arm of innate host immunity (29, 
48).  Survival of H. ducreyi strains unable to express DsrA was strongly inhibited in pigs 
and humans (17, 20), and dltA mutants had diminished but not absent viability in 
experimentally infected humans (41).  Furthermore, DsrA facilitates binding to the 
extracellular matrix (ECM) protein vitronectin as well as human keratinocytes in vitro, 
though these two functions do not appear to be directly linked (20).  DltA, a 
carbohydrate-binding lectin, was identified by its binding affinity toward lactose-
containing sugar moieties (48).  Though a direct link between DltA carbohydrate binding 
and serum resistance has not been established, DltA lectin activity may have a positive 
impact on bacterial binding to host glycoprotein structures (48).   
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DsrA is a member of the oligomeric coiled adhesin (Oca) family of bacterial outer 
membrane proteins.  Also referred to as type Vc oligomeric autotransporters (35), Oca 
protein monomers assemble to form a stalk-like coiled stem structure, terminating in a 
globular “head” domain.  Like H. ducreyi DsrA, Oca family members found in pathogenic 
Yersinia, Moraxella, and Escherichia species have been shown to confer both ECM 
adherence and serum resistance phenotypes (1, 54, 73, 77).  We identified another Oca-
family adhesin in H. ducreyi that is homologous to DsrA, and its contribution to 
virulence is discussed in greater detail in Chapter 3 of this work.   
 
Evasion of host immunity 
 The abundance of inflammatory cells within the chancroid lesion creates a very 
hostile environment for bacteria.  They are subject to engulfment by professional 
phagocytic cells or attacked by reactive oxygen and nitrogen intermediates produced by 
PMN.  H. ducreyi expresses proteins that subvert both these defense mechanisms to 
enable survival in vivo.  Researchers noted in several instances that H. ducreyi appears to 
evade engulfment by professional phagocytic cells (12, 13), and later showed that this 
antiphagocytic activity extends to nearby inert foreign particles as well (3, 92).  First 
identified as large supernatant proteins found in H. ducreyi broth cultures (89),  LspA1 
and 2 were found to be essential in both rabbit (88) and human (42) models of chancroid.  
Mock et al. illustrated that the LspA proteins interfere with Src tyrosine kinase signaling 
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in macrophages, thereby blocking phagocytosis (56), which hampers host efforts to clear 
the chancroid lesion of H. ducreyi. 
 Defense against the oxidative burst is provided by enzymes that break down toxic 
reactive species into less toxic products.  Superoxide dismutase, encoded by the sodC 
gene, is responsible for the detoxification of the superoxide radical (75).  Located in the 
periplasmic space, SodC uses a coordinated Cu-Zn catalytic center to convert superoxide 
O2- into the less reactive species hydrogen peroxide (H2O2) and H2O.  In this manner, H. 
ducreyi circumvents intracellular damage caused by this PMN-generated antibacterial 
response and is able to withstand oxidative stress within the chancroid lesion.  San Mateo 
et al. elegantly showed that an H. ducreyi strain unable to express SodC was profoundly 
attenuated in the pig model of chancroid; cyclophosphamide-induced depletion of PMN 
in the host prior to inoculation rescued the virulence phenotype of the sodC mutant (76).  
Discordantly, SodC was found nonessential to H. ducreyi virulence in the human 
chancroid model (16).  The cause of this difference is unknown, but it may reflect 
differences in the interaction of swine versus human immune cells with H. ducreyi, or an 
artificially elevated contribution of SodC to H. ducreyi virulence in a non-natural host 
(16).   
 Several H. ducreyi gene products that seem to have direct correlation to virulence 
have proven to be nonessential for virulence in animal models of chancroid (7, 95).  Two 
of these proteins are the contact hemolysin HhdB and the cytolethal distending toxin 
(CDT).  The contact hemolysin is a Serratia-type pore-forming toxin (36) expressed from 
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the hhdBA locus, with HhdA facilitating the transport of the active subunit HhdB across 
the cytoplasmic membrane (63).  HhdB is active against human foreskin fibroblasts (5), 
the HaCaT keratinocyte cell line (62), macrophages, and lymphocytes (93).  This activity 
is not diffusible; HhdB is associated with the bacterial surface, and requires contact 
between H. ducreyi and the target cells to induce cytotoxicity (5).  In contrast, CDT is a 
soluble factor actively secreted by H. ducreyi.  CDT is a heterotrimeric complex of CdtA, 
CdtB, and CdtC polypeptides capable of intoxicating a wide range of eukaryotic cell types 
(reviewed in (80)).  CDT causes cell-cycle arrest in target cells, and its name is derived 
from the cells’ distended morphology as growth continues without division.  Apoptotic 
cell death follows intoxication, usually after 24 to 36 hours.  CDT homologs expressed by 
other gram-negative bacteria have been implicated as potential modulators of host 
immunity (38, 79), making CDT an especially intriguing candidate for study with regard 
to H. ducreyi pathogenesis.  An H. ducreyi cdtC hhdB double mutant was tested in both 
swine (Kawula Lab, unpublished data) and human (95) chancroid models, and its 
virulence was found to be equivalent to wild type.  Thus, the current literature reports 
both hemolysin and CDT as being dispensable for H. ducreyi virulence.   Some 
controversy exists around this assessment of the role of CDT in H. ducreyi pathogenesis.  
Though the cdtC hhdB double mutant used in the human challenge model cannot form 
intact CDT holotoxin (a CdtA-CdtB-CdtC trimer) it does express CdtB, the primary 
toxigenic subunit.  Delivery of CdtB alone into cultured cells can recapitulate 
cytopathology seen in CDT holotoxin-exposed cells (47, 51, 53).  Therefore, we asserted 
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that a cdtC-deficient strain of H. ducreyi may have residual toxicity, and was 
inappropriate for use as a “CDT-null” mutant for evaluation of CDT toxicity in models of 
H. ducreyi pathogenesis.  Continued investigations to this effect are discussed at greater 
length in Chapter 4.   
 In the context of global public health, H. ducreyi and its contribution to the spread 
of epidemic sexually-transmitted infections like HIV are a serious cause for concern.  
This pathogen is keenly adapted to survive exclusively within the human population, and 
does so by controlling or avoiding host defenses.  By studying the means by which H. 
ducreyi achieves its molecular subterfuge, we can begin to design intelligent ways to 
counteract H. ducreyi virulence, build immunity to chancroid, and ultimately eradicate 
this serious threat to people of the developing world.  The following chapters describe our 
efforts to elucidate H. ducreyi pathogenesis using the swine experiment model of 
chancroid to explore 1) the nature of the humoral response against H. ducreyi, 2) a novel 
determinant of H. ducreyi adherence to host collagen, and 3) the heretofore 
underestimated contribution of CDT to H. ducreyi infection.   
19 
 
 
Figure 1.1.  Natural chancroid lesions in the human host. 
Panel A illustrates a cluster of chancroid ulcers near the penile frenulum.  Note the 
irregular shape, purulent appearance, and bleeding points within the floor of the lesion.  
Panel B shows both the primary frenular chancroid lesions as well as rupture of an 
inguinal bubo secondary to ascension of the inflammatory response to the draining 
lymph node.   
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 Haemophilus ducreyi is the etiologic agent of the sexually transmitted genital ulcer 
disease chancroid.  Neither naturally-occurring chancroid nor experimental infection 
with H. ducreyi results in protective immunity.  Likewise, a single inoculation of H. 
ducreyi does not protect pigs against subsequent infection.  Accordingly, we used the 
swine model of chancroid infection to examine the impact of multiple inoculations on a 
host’s immune response.  After three successive inoculations with H. ducreyi, pigs 
developed a modestly protective immune response evidenced by the decreased recovery 
of viable bacteria from lesions.  All lesions biopsied 2 days after the first and second 
inoculations contained viable H. ducreyi cells, yet only 55% of the lesions biopsied 2 days 
after the third inoculation did.  Nearly 90% of the lesions biopsied 7 days after the first 
inoculation contained viable H. ducreyi cells, but this percentage dropped to only 16% 
after the third inoculation.  Between the first and third inoculations, the average recovery 
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of CFU from lesions decreased approximately 100-fold.  The reduced recovery of bacteria 
corresponded directly with a fivefold increase in H. ducreyi-specific antibody titers and 
the emergence of bactericidal activity.  These immune sera were protective when 
administered to naïve pigs prior to challenge with H. ducreyi.  These data suggest that 
pigs mount an effective humoral immune response to H. ducreyi after multiple exposures 
to the organism. 
 
Introduction 
 
Chancroid is a sexually transmitted infection often seen in resource-poor tropical 
areas (34) and is a prevalent genital ulcer disease in certain areas of Asia, Africa, and Latin 
America (31, 34, 35).  As both cross-sectional cohort studies and prospective longitudinal 
studies indicate that all genital ulcer disease (13, 23, 41, 51) and chancroid in particular 
(31, 33) increase the risk for sexual transmission and acquisition of human 
immunodeficiency virus type 1 (HIV-1), control of chancroid could provide an effective 
intervention strategy against the spread of human immunodeficiency virus type 1 (18, 21, 
27, 34, 37, 41, 44, 52).  Control of chancroid is complicated by the fact that natural 
chancroid infection does not appear to protect against subsequent infection (6, 25, 43).  
Concordantly, a single experimental infection with Haemophilus ducreyi does not protect 
human volunteers against subsequent experimental challenge (4, 49). 
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Humans mount what appears to be a delayed-type (type IV) hypersensitivity 
reaction in response to H. ducreyi (22, 32, 38, 49).  This response is neither protective 
against future infection nor effective at clearing chancroid infections as lesions can persist 
for weeks or months and ulcer resolution is often incomplete in the absence of antibiotic 
therapy (34).  One possible reason for the ineffective nature of this response is that cell-
mediated immunity is highly effective at killing intracellular bacteria and viruses (30), yet 
the majority of H. ducreyi present in chancroid lesions are extracellular (5). 
While the delayed-type (type IV) hypersensitivity response appears ineffective at 
preventing future chancroid infections, it is unclear what sort of response would be 
protective.  The extracellular existence of the bacteria suggests that a humoral immune 
response could be protective against infection.  We repeatedly exposed pigs to H. ducreyi 
in an attempt to elicit and identify a protective immune response in the swine model of 
chancroid.  Pigs, like humans, are not protected from subsequent infection by a single 
exposure to H. ducreyi.  However, after three inoculations at 14-day intervals, pigs 
developed a modest but significant level of protective immunity against H. ducreyi.  
Protection was defined not as an absolute block of infection but rather as a reduction in 
disease severity as indicated by reduced recovery of viable H. ducreyi cells.  Passive 
transfer of immune serum protected naïve animals against challenge with H. ducreyi.  
These results from the swine model support the idea that humoral immunity to H. 
ducreyi could provide protection against infection by this organism. 
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Materials and Methods 
 
Bacterial inoculum preparation.  
The inoculum was prepared and quantified as previously described (29, 45). 
Briefly, H. ducreyi strain 35000HP (gift from Stanley Spinola) was grown from a freezer 
stock and passed once on chocolate agar plates containing 1.5% (wt/vol) Bacto agar, 2.5% 
brain heart infusion (BHI), 1% hemoglobin, 1% IsoVitaleX (all from Becton Dickinson, 
Cockeysville, Md.), 5% newborn calf serum, and 5% fetal bovine serum (Life 
Technologies, Inc., Rockville, Md.) at 35°C in a humidified incubator with 5% CO2.  
Vancomycin, when used, was added to growth media at a concentration of 3 μg/ml. 
 
Animals.  
 Juvenile female crossbred (Yorkshire-Landrace crossed with Hampshire-Duroc 
[hereafter, Yorkshire cross]) pigs were employed as previously described (29).  Pigs were 
housed in individual enclosures at North Carolina State University College of Veterinary 
Medicine in a P2 containment facility accredited by the American Association for 
Accreditation of Laboratory Animal Care.  All pigs were 6 weeks old at the beginning of 
the study.  Animals were sedated for procedures with 0.3 ml of a TKX cocktail per 22.7 kg 
of body weight.  The cocktail consisted of tiletamine HCl-zolazepam HCl (each, 50 
mg/ml), (Telazol; Fort Dodge Laboratories, Fort Dodge, Iowa), ketamine HCl (50 mg/ml) 
(Fort Dodge Laboratories), and xylazine (50 mg/ml) (Miles Laboratories, Shawnee 
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Mission, Kans.).  Atropine sulfate (Phoenix Scientific Inc., Joseph, Mo.) was given in the 
amount of 0.5 ml to 1 ml, depending on the size of the animal, in order to slow bronchial 
secretion and prevent aspiration. 
 
Inoculation.  
 Eight sites on the dorsal side of each ear for a total of 16 sites per pig were 
inoculated with Multi-Test multiple skin test applicators (Lincoln Diagnostics, Decatur, 
Ill.) as previously described (29, 49).  Two sites per ear were inoculated with the Multi-
Test applicators loaded with each of the following: 106 CFU of H. ducreyi 35000HP, 107 
CFU of H. ducreyi 35000HP, 106 CFU of heat-killed H. ducreyi 35000HP, or 10 μl of 
sterile phosphate-buffered saline (PBS).  This inoculation scheme resulted in an estimated 
delivered dose of 4 × 103 to 4 × 104 CFU to the dermis and epidermis of the skin (46). 
Inoculations were repeated at 14-day intervals (Figure 2. 1).  Inoculations were carefully 
placed such that no two successive sites overlapped. In addition to the pigs that received 
all three inoculations, one pig received no inoculations, and two pigs received only the 
first inoculation. 
 
Biopsy of samples.    
 Inoculation sites were excised 2 or 7 days following each inoculation with 6-mm-
diameter skin punches (Acuderm, Ft. Lauderdale, Fla.).  Tissues were bisected with sterile 
scalpels (Acuderm).  One half of each biopsy was fixed in 4% paraformaldehyde in PBS, 
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while the other half was minced and plated on chocolate agar plates with 3 μg of 
vancomycin per ml for recovery and enumeration of viable H. ducreyi.  If recovery plates 
were excessively contaminated, the recovery data were not included in our analyses.  
Fixed sample halves were embedded in paraffin, sectioned, stained with hematoxylin and 
eosin (Histopathology Reference Laboratory, Richmond, Calif.), and blindly scored for 
histological severity according to our previously developed scoring system (46) (data not 
shown). 
 
Serum and complement collection.  
 Sera were collected weekly from all animals.  One of the animals receiving a single 
inoculation suffered a leg injury and was euthanized prior to the completion of the study.  
This animal had serum collected for the final time on day 42 instead of day 49. 
Collected blood was allowed to clot overnight at 4°C.  Blood was centrifuged at 
room temperature in a bench top centrifuge at 408 × g for 10 min prior to the removal of 
serum.  Serum was centrifuged again at room temperature in a bench top centrifuge at 
408 × g for 10 min before aliquots were frozen at −80°C. 
Pig complement was collected from separate naïve Yorkshire cross pigs.  Blood 
was drawn from animals and clotted at 37°C for 30 min.  Serum was removed and 
centrifuged at 4°C at 2,000 × g for 10 min.  Serum was passed through a 0.45-μm syringe 
filter, aliquoted, and frozen immediately at −80°C.  Aliquots were used only once as an 
active complement source. 
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Immune bactericidal assays.  
 H. ducreyi 35000HP was grown for 16.5 h from a freezer stock on chocolate agar 
at 35°C with 5% CO2.  Cells were harvested and suspended in 2 ml of BHI broth (Becton 
Dickinson, Cockeysville, Md.). Cells were vortexed for 5 s and allowed to settle for 5 min 
in order to remove large aggregates of H. ducreyi.  After settling, the top 1 ml of the 
bacterial solution was removed and the cell density was adjusted such that the final 
concentration of bacteria was 100 to 500 CFU per 80 μl of media. 
Bactericidal assays were performed as described (15, 16).  Briefly, assays were 
performed in sterile 96-well plates (Falcon microtest tissue culture plate; Becton 
Dickinson, Franklin Lakes, N.J.).  Each test well received 80 μl of cells and 10 μl (or 10%) 
of heat-inactivated test serum.  Plates were incubated for 15 min at 35°C with 5% CO2 
after which 10 μl (or 10%) of either heat-inactivated or active fresh pig complement 
serum was added.  Plates were mixed by tapping and then incubated for an additional 45 
min.  Bacteria were quantified by plating 60 μl from each well onto chocolate agar.  
Percent survival was determined for each immune serum sample tested by dividing the 
number of colonies that survived exposure to fresh serum complement by the number of 
colonies that survived with heat-inactivated serum complement and multiplying by 100.  
To ensure that the serum complement did not kill the bacteria in an antibody-
independent fashion, we used BHI media in place of the serum antibody source in 
bactericidal assays.  The average percent survival in the BHI medium was consistently 
34 
greater than 100% (data not shown), indicating that complement containing serum, in 
the absence of antibody, did not kill the bacteria.  Samples were assayed in triplicate on 
three separate days. 
 
Serum IgG determination.  
 Total serum immunoglobulin G (IgG) was measured following the manufacturer's 
protocol with a pig serum IgG enzyme-linked immunosorbent assay (ELISA) kit (Bethyl 
Laboratories, Montgomery, Tex.).  H. ducreyi-specific IgG was measured by a similar 
method; however, instead of coating microplate wells (96-well MaxiSorp; Nalge Nunc, 
Rochester, N.Y.) with goat anti-pig IgG capture monoclonal antibody, wells were coated 
with whole-cell H. ducreyi lysate at a concentration of 10 μg/ml in 100 mM sodium 
carbonate, pH 9.6.  The lysate was made by sonicating plate-grown H. ducreyi 35000HP 
on ice in a mixture of 50 mM sodium phosphate (monobasic) and 300 mM sodium 
chloride, pH 7.8. Insoluble particles and unbroken whole cells were removed from the 
sonicate mixture by centrifugation at 800 × g for 5 min.  The sonicate was filtered (pore 
size, 0.2 μm) and assayed for total protein content (DC protein assay; Bio-Rad 
Laboratories, Hercules, Calif.).  Aside from the coating, both ELISA formats were 
performed identically and in tandem.  Coated wells were blocked with 1% bovine serum 
albumin in Tris-buffered saline (50 mM Tris, 0.15 M sodium chloride, pH 8), then 
washed with TBST (Tris-buffered saline plus 0.05% Tween 20).  Sera were serially diluted 
twofold in TBST containing 1% bovine serum albumin, and a calibrator serum included 
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with the ELISA kit was run to assess the performance of each assay.  Sera were incubated 
in the coated plates and washed with TBST before being incubated with a goat anti-pig 
IgG secondary antibody conjugated to horseradish peroxidase.  After sera were washed 
again with TBST, tetramethyl benzidine detection substrate (KPL, Gaithersburg, Md.) 
was added to each well, allowed to develop, and stopped by the addition of 2 M H2SO4.  
The optical density at 450 nm (OD450) was measured with a SpectraMax 340PC 
microplate spectrophotometer, and response curves were calculated with SOFTmax PRO 
software (Molecular Devices, Sunnyvale, Calif.).  This software was also used to perform 
four-parameter curve fitting for the data.  Titers were calculated by solving the four-
parameter equation at an OD450 value of 15 times the assay background.  The assay 
background was defined as the mean OD450 of all assay blank wells (containing all 
reagents except serum), plus three times the standard deviation.  Response curves for 
general visual comparison were graphed with Microsoft Excel. 
 
Passive transfer.  
 Pigs were infused with 25 ml of serum with a 30-ml syringe (Becton Dickinson, 
Franklin Lakes, N.J.) attached to a 6-in. male luer lock adapter extension set (Baxter 
Healthcare Corporation, Deerfield, Ill.) and an 18-gauge needle (Becton Dickinson, 
Franklin Lakes, N.J.).  Two pigs were infused with normal pig serum, and five pigs were 
infused with serum from a repeatedly inoculated pig.  One day after infusion, pigs were 
inoculated according to the procedure described above.  Each pig was inoculated with live 
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bacteria at eight sites per ear, for a total of sixteen live inoculations, and the entire biopsy 
of each lesion was minced and plated for recovery.  Day 7 recovery data from one pig 
infused with bactericidal serum were not included in the Results section due to 
overwhelming bacterial and fungal contamination on the recovery plates.  
 
Statistical methods.  
 Statistical analysis was performed with Sigma Stat version 2.0 (Jandel Scientific, 
San Rafael, Calif.) and SAS software (SAS Institute Inc., Cary, North Carolina).  Bacterial 
recovery counts were modeled with gamma regression modeling as a function of the day 
of the biopsy, and generalized estimation equations were used to adjust the data for 
random effects.  The percentages of positive biopsies were analyzed via logistic regression 
analysis.  This hierarchical model was used to accommodate the effect of collecting 
multiple biopsies from single animals.  Data analysis with t tests was used to compare two 
groups for bactericidal assays, H. ducreyi-specific IgG titers, and recovery data from 
serum-infused animals. 
 
Results 
 
Recovery of viable bacteria decreased with repeated exposure to H. ducreyi.  
Five pigs were inoculated with H. ducreyi three times at 2-week intervals (Fig. 2.1).  
Two and seven days following each inoculation, punch biopsies of inoculation sites were 
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collected and evaluated for lesion severity and recovery of live H. ducreyi.  Biopsy results 
from both inoculation dilutions are presented together (Fig. 2.2), since analysis revealed 
that percentages of culture-positive lesion biopsies were identical for all time points (data 
not shown).  All biopsies collected 2 days following the first and second inoculations 
contained live H. ducreyi, whereas only 55% of total biopsies taken 2 days after the third 
inoculation were culture positive.  We were significantly more likely to recover bacteria 
from lesions biopsied 7 days after the first inoculation than after the third (89 versus 16% 
recovery; odds ratio, 45.33; 95% confidence interval, 4.89 to 420.48; P = 0.0008) (Fig. 2.2). 
The average number of bacteria recovered from culture-positive lesions also 
dropped with repeated inoculations (Fig. 2.2).  Gamma regression modeling revealed that 
significantly more bacteria were recovered after the first versus the third inoculation on 
both day 2 (odds ratio, 77.138; 95% confidence interval, 14.86 to 400.41; P = <0.0001) and 
day 7 (odds ratio, 310.00; 95% confidence interval, 61.30 to 1,567.75; P = <0.0001).  
Decreases in both the number of culture-positive lesions and in CFU recovered per lesion 
suggest that after three successive inoculations, pigs developed a modest but significant 
level of protection against H. ducreyi infection. 
 
H. ducreyi-specific serum IgG levels increased over the course of multiple H. ducreyi 
inoculations.  
 
 We measured total and H. ducreyi-specific serum IgG levels at three time points, 
preinoculation (day 0), 1 week after the second inoculation (day 21), and 2 weeks after the 
final inoculation (day 42). 
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H. ducreyi-specific serum IgG titers were greater in the day 42 sera of pigs 
inoculated three times than in the day 21 or day 0 sera of the same animals (Table 2.1).  
Day 42 sera from these pigs had 4.8-fold more H. ducreyi-specific IgG than sera collected 
from the same animals prior to inoculation (Table 2.1) (P = 0.019, t test).  To determine if 
the elevated antibody titers in this group of pigs were due to multiple inoculations rather 
than to an age-dependent effect, we evaluated serum from an animal that was inoculated 
once on day 0.  While there was an initial increase in H. ducreyi-specific IgG, this 
elevation did not persist over the course of the experiment (Table 2.1).  This result 
indicated that the increase in H. ducreyi-specific IgG resulted from repeated exposure to 
H. ducreyi and not from a nonspecific change in the pigs' immune responses.  There were 
no appreciable changes in the levels of total IgG in these sera over the course of the 
experiment (data not shown). 
 
Serum from pigs inoculated multiple times displayed enhanced bactericidal activity 
against H. ducreyi. 
  
We used an immune bactericidal assay to determine if the observed increases in 
H. ducreyi-specific antibody titers corresponded with increased bactericidal activity.  We 
compared the bactericidal activity of preimmune sera (day 0), sera collected 2 weeks after 
the first inoculation (day 14), 2 weeks after the second inoculation (day 28), and 3 weeks 
after the third inoculation (day 49) (Fig. 2.1).  We also tested sera collected from one 
uninoculated pig and two pigs that received only one inoculation. 
39 
The average percent survival of H. ducreyi in preimmune sera was 95% ± 35%, 
indicating that none of the preimmune serum samples (n = 8) exhibited bactericidal 
activity. 
The average percent survival of H. ducreyi in day 14 sera of animals receiving only 
one inoculation was 35% ± 32% (n = 7).  The average percent survival of bacteria in day 
28 sera from twice-inoculated animals was 11% ± 17%.  In sera drawn 3 weeks after the 
third and final inoculation, the average percent survival of H. ducreyi was 23% ± 10% 
(Fig. 2.3).  The average percent survival of H. ducreyi in sera from the uninoculated pig 
was approximately 100% regardless of the day the serum was drawn (Fig. 2.3).  This result 
indicated that emergence of bactericidal activity was not an age-related phenomenon. 
We also wanted to determine if this enhanced bactericidal activity resulted from 
just the first inoculation or was dependent upon the multiple inoculation protocol.  While 
day 14 sera of animals receiving a single inoculation displayed enhanced bactericidal 
activity, the average percent survival of H. ducreyi in sera drawn 4 weeks after a single 
inoculation was 81 ± 48%.  A similar 77 ± 35% of bacteria survived in sera collected 7 
weeks after a single inoculation (Fig. 2.3).  In fact, sera drawn at the end of the study from 
pigs that had received a single inoculation did not exhibit a statistically significant 
difference in bactericidal activity compared to activity in preimmune serum.  This finding 
suggested that while one inoculation with H. ducreyi increased bactericidal antibody 
titers, this enhancement was transient in the absence of repeated inoculations. 
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Day 49 sera from pigs inoculated three times had statistically greater bactericidal 
activity than all preimmune sera (P = <0.001, t test).  Day 49 sera from this group of pigs 
also had much greater bactericidal activity than day 49 sera from animals that received 
one inoculation or that remained uninoculated (Fig. 2.3).  The increased bactericidal 
activity of sera collected from the animals receiving three inoculations corresponded with 
total H. ducreyi-specific IgG titers as measured by ELISA. 
 
The passive transfer of bactericidal serum protected naïve animals against H. ducreyi 
challenge.  
 
We hypothesized that elevated titers of H. ducreyi-specific antibodies, possibly 
through the action of complement-mediated killing, were providing the animals that 
received repeated inoculations with protection against H. ducreyi challenge.  To test this 
idea, we transfused immune serum from a pig that received multiple inoculations into 
naïve pigs before H. ducreyi challenge.  As a control, we also challenged naïve pigs infused 
with serum from an uninoculated pig (normal pig serum).  All lesions collected from pigs 
infused with normal pig serum contained viable bacteria.  Two days after inoculation, 
82.5% of the biopsies collected from all immune serum-infused animals contained viable 
bacteria. Seven days after inoculation, this percentage dropped to 20%.  Two of the pigs 
infused with immune serum yielded exclusively sterile lesions on day 7.  Only 25 and 43% 
of day 7 lesions from the other two animals infused with immune serum contained viable 
bacteria (Fig. 2.4).  The difference in the percentages of H. ducreyi-positive biopsies per 
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pig for animals infused with the immune versus normal pig serum was statistically 
significant for day 7 biopsies (P = 0.006, t test). 
 
Discussion 
 
After three successive experimental chancroid infections, pigs developed a 
modestly protective immune response against H. ducreyi.  The recovery of viable 
organisms from lesion biopsies as well as the number of culture-positive lesions decreased 
throughout the experiment.  This decreased recovery corresponded directly with 
increased serum levels of H. ducreyi-specific IgG and enhanced bactericidal activity.  This 
finding suggested that the humoral component of the immune response was involved in 
mediating protection against H. ducreyi.  Because naïve pigs infused with serum from a 
pig that received repeated inoculations were protected against H. ducreyi challenge, we 
concluded that the humoral component of the immune response was playing a major role 
in mediating protection. 
The successful transfer of protection along with the transfer of immune serum 
distinguishes our findings from similar experiments performed with the temperature-
dependent rabbit model of chancroid (40).  In the temperature-dependent rabbit model, a 
single previous experimental infection with H. ducreyi (26), immunization with cell wall 
components (26), a pilus preparation (11, 12), or purified hemolysin (14) protected 
rabbits against future experimental challenge.  However, passive transfer of whole-cell H. 
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ducreyi-specific or pilus-specific IgG fractions did not confer protection (12).  Passive 
transfer was not successful despite the fact that passively immunized rabbits displayed 
sustained, titratable antibody levels throughout the experiment (12).  Perhaps this result 
was due to the fact that immune rabbit sera do not possess bactericidal activity against H. 
ducreyi (20, 28). 
The protection observed in the pig model may initially appear to contradict 
conclusions drawn from the human challenge model of chancroid.  Previous 
experimental infection neither prohibits nor inhibits the development of a second 
experimental infection in human volunteers (4, 49).  However, careful comparison of 
recovery data from the human and swine models of chancroid revealed similarities.  
Human challenge studies with a single infection reported that 57 to 100% of lesion 
biopsies contain viable H. ducreyi (2, 3, 7, 8, 19, 39, 48, 50, 53, 54).  In a human challenge 
reinfection study, viable H. ducreyi was recovered from 83% of biopsies from previously 
infected people and 67% of biopsies from individuals infected for the first time (4).  These 
percentages are consistent with the percentages of culture-positive biopsies observed in 
pigs after the first and second inoculations.  Two and seven days after the first 
inoculation, 100 and 89% of the swine biopsies were culture positive, respectively.  All 20 
of the biopsies collected 2 days after the second inoculation were positive, and 42% of the 
biopsies collected 7 days after the second inoculation were also culture positive.  The 
significant drops in both the recovery and the number of culture-positive lesions did not 
occur until after the third inoculation. 
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It was concluded that experimental human infection to the pustular stage of 
disease did not protect people against a subsequent chancroid infection (4) because a 
naïve control group and a group of individuals that had been previously experimentally 
infected exhibited equivalent abilities to form both pustules and papules.  However, after 
a single previous inoculation, pigs also developed papules and pustules in response to 
inoculation with H. ducreyi.  Pig lesion histology scores dropped significantly only after 
the third inoculation (data not shown).  After the third inoculation, the average histology 
scores for the PBS and live inoculations and the heat-killed bacteria inoculations were 
virtually identical.  While we saw the development of protective immunity in the swine 
model of chancroid infection, the results from the first two rounds of pig inoculations are 
similar to results from the human challenge model of chancroid infection. 
Pigs developed antibodies to H. ducreyi after single (29) and repeated 
inoculations. In contrast, initial (38, 48) and repeated (4) experimental human infection 
up to 14 days or the pustular stage does not evoke an antibody response to bacterial 
proteins or lipooligosaccharides.  Unlike experimental infection, naturally occurring 
chancroid results in the development of a humoral response to H. ducreyi (1, 9, 10, 17, 36, 
42, 47).  Once chancroid develops, the likelihood of producing H. ducreyi-specific 
antibodies increases along with ulcer duration (10, 42).  Patients with genital ulcers 
persisting in excess of 4 weeks have the strongest humoral response (10). 
Antibodies may mediate protection through enhanced opsonization, increased 
bactericidal activity, blockage of attachment, or some combination of all three effects.  
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While people with naturally occurring chancroid infection develop antibodies against H. 
ducreyi, these antibodies are not bactericidal (20).  In contrast, antibodies produced by 
pigs that received three inoculations were bactericidal against H. ducreyi, and serum 
containing these antibodies conferred enhanced bacterial clearance when transferred to 
naïve animals.  This outcome strongly suggested that the bactericidal ability of the H. 
ducreyi-specific swine antibodies provided protection against chancroid. 
The development of bactericidal activity in pigs was specifically dependent on the 
multiple inoculation protocol as the uninoculated animal did not display enhanced 
bactericidal ability and animals receiving single inoculations displayed only transient 
increases in bactericidal activity.  This greatly enhanced bactericidal activity was 
accomplished with only a fivefold increase in H. ducreyi-specific antibody titer.  While 
this increase is not a large elevation in titer, protective antibody titers following natural 
infections are often lower than the titers seen postvaccination.  For example, both 
previous natural infection and vaccination against hepatitis B infection are protective, but 
after natural seroconversion, the average geometric mean titers of anti-hepatitis B 
antibodies are 41-fold lower than titers at the peak of response in vaccinees (24). 
We examined the longevity of the protection seen in the three-times inoculated 
animals by inoculating a single pig from this group a fourth time with H. ducreyi 70 days 
after the third inoculation.  While 25% of the lesions biopsied 2 days after the fourth 
inoculation yielded live organisms, none of the lesions biopsied 7 days after the fourth 
inoculation yielded live organisms (data not shown).  Reduced bacterial recovery once 
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again corresponded with increased bactericidal ability as 66 ± 18% of H. ducreyi cells 
survived in serum drawn just prior to the fourth inoculation, while only 15 ± 4% of the 
cells survived in serum drawn 7 days after the fourth inoculation (data not shown).  The 
rapid development of bactericidal activity suggests the existence of antigen-specific 
memory B cells and implies that memory B cell generation will be an important 
component of any successful human H. ducreyi vaccine.  
We have begun to identify targets of swine antibodies produced in response to 
repeated H. ducreyi exposure.  All pigs receiving repeated inoculations appear to develop 
antibodies to the same distinct set of H. ducreyi antigens (data not shown).  We hope to 
identify both the specific antigens and their roles as bactericidal antibody targets.  The 
comparison of proteins eliciting antibody responses could also be important in 
understanding how a humoral response is protective in pigs but not in people. 
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Table 2.1.  Summary of H. ducreyi-specific IgG titers from an uninoculated pig and from 
pigs inoculated one and three times 
Titer -1 (SD) 
Treatment (n)a 
Day 0b Day 21c Day 42d 
Three inoculations (4/5) 54 (3.2) 190 (1.8)e 260 (1.8) 
One inoculation (1/2) 24  56 25 
Uninoculated (1/1) 120 (1.1) 65 (1.0) 50 (1.0) 
a  n, number of pigs assayed/number of pigs treated 
b  Day 0, preimmune serum 
c  Day 21 serum was collected at the time corresponding to 1 week after the second set of 
inoculations (See Figure 2.1). 
d  Day 42 serum was collected 2 weeks after the time corresponding to the third 
inoculation. 
e  Only two pigs were assayed at day 21. 
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Figure 2.1.  Timeline of repeat inoculation study with Yorkshire cross pigs.  
Inoculations occurred at 14-day intervals.  The ears of the pigs were inoculated with live 
H. ducreyi at four sites per ear per inoculation.  Lesion biopsies were collected either 2 or 
7 days after each inoculation.  Five pigs were inoculated three times, two pigs were 
inoculated once, and one pig was never inoculated.  Serum was collected from all pigs on 
a weekly basis. 
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Figure 2.2.  Percentage of all half-biopsies which were positive for recovery (A) and 
average recovery of CFU per half-biopsy (B).  
Data are from five pigs inoculated three times at 14-day intervals.  Four lesions from live 
H. ducreyi inoculations were collected from each animal 2 and 7 days after each 
inoculation.  CFU per half-biopsy were enumerated by mincing and plating half of each 
biopsy on chocolate agar.  Recovery of one bacterium was sufficient to mark the lesion 
biopsy as positive for recovery.  (A) Fraction numerators are the number of lesion 
biopsies positive for recovery, whereas denominators are the total number of lesion 
biopsies analyzed at that time point. Bars represent percentages of culture-positive lesion 
biopsies.  (B) Average CFU per half-biopsy was calculated for each time point by dividing 
the total CFU recovered by the number of biopsies analyzed.  This graph displays means 
and standard deviations. 
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Figure 2.3.  Average percent survival of H. ducreyi in immune bactericidal assays with 
heat-inactivated pig sera collected after three, two, one, or zero inoculations with H. 
ducreyi. 
Bars represent average percent survival of H. ducreyi in sera drawn on the day indicated 
after treatment described.  The day 0 data bar represents survival of H. ducreyi in sera 
drawn from all eight animals prior to any inoculations.  Day 14 data bars represent assays 
done with serum drawn from an uninoculated animal and sera drawn from seven pigs 
that had received one inoculation on day 0.  Day 28 data bars represent assays done with 
serum drawn from one uninoculated pig, sera drawn from two pigs that received only one 
inoculation on day 0, and sera drawn from five pigs that had received two prior 
inoculations on day 0 and day 14.  Day 49 data bars represent the percent survival of H. 
ducreyi in sera drawn on day 49 from three groups of animals: a single uninoculated pig, 
one pig that had been inoculated once on day 0, and five pigs that were inoculated three 
times on days 0, 14, and 28.  Error bars illustrate standard deviations.  Data were 
subjected to an analysis of variance. 
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Figure 2.4.  Average percentages of H. ducreyi-positive biopsies per pig after passive 
transfer of immune or normal pig serum (NPS) to naïve animals. 
Pigs were inoculated with H. ducreyi 1 day after infusion with either NPS or immune 
serum. Lesion biopsies were collected either 2 or 7 days after inoculation.  Entire lesion 
biopsies were minced and plated for recovery.  Bars represent the average percentage of 
culture-positive biopsies per pig.  Error bars represent standard errors of the means.  
Analysis via t test revealed that while there was not a statistically significant difference in 
the percentage of culture-positive biopsies per pig on day 2, there was on day 7 (P = 
0.006). 
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Haemophilus ducreyi, the etiologic agent of the sexually transmitted genital ulcer 
disease chancroid, has been shown to associate with dermal collagen fibers within 
infected skin lesions.  Herein we describe NcaA, a previously uncharacterized outer 
membrane protein that is important for H. ducreyi collagen binding and host 
colonization.  An H. ducreyi strain lacking the ncaA gene was impaired for adherence to 
type I collagen but not fibronectin (plasma or cellular forms) or heparin.  The mutation 
had no effect on serum resistance or binding to HaCaT keratinocytes or human foreskin 
fibroblasts in vitro.  E. coli expressing H. ducreyi NcaA bound to type I collagen, 
demonstrating that NcaA is sufficient to confer collagen attachment.   The importance of 
NcaA in H. ducreyi pathogenesis was assessed using both swine and human experimental 
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models of chancroid.  In the swine model, 20% of lesions from sites inoculated with the 
ncaA mutant were culture-positive for H. ducreyi 7 days after inoculation compared to 
73% of wild type-inoculated sites.  The average number of CFU recovered from mutant-
inoculated lesions was also significantly reduced compared to wild type at both 2 and 7 
days after inoculation.  In the human challenge model, 8 of 30 sites inoculated with wild 
type H. ducreyi progressed to the pustular stage, compared to 0 of 30 sites inoculated with 
the ncaA mutant.  Together these results demonstrate that collagen binding protein NcaA 
is required for H. ducreyi infection.     
 
Introduction 
 
Haemophilus ducreyi is the etiologic agent of the sexually transmitted genital ulcer 
disease (GUD) chancroid.  Chancroid is rare in the United States and Western Europe.  It 
is prevalent in tropical resource-poor regions and is endemic in certain areas of Africa 
and Asia (11, 38, 39, 47), where there is also a significant confluence of chancroid 
infection and HIV-1 seropositivity (17, 30, 40).  In these regions, case control studies have 
shown that the relative risk of acquiring HIV infection for GUD patients ranged from 
odds ratios of 3 to 18.2 (20, 49, 60).  Per individual sexual act, GUD produces a 4- to 23-
fold enhancement of HIV acquisition (22, 33), and GUD in an HIV-positive person 
doubles the relative risk per coital act of viral transmission to an HIV-negative partner 
(22, 61).  Furthermore, HIV-positive chancroid patients often present ulcers that are 
more severe, longer-lasting, and more difficult to cure (31, 45).  These observations 
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outline the strong synergistic relationship between GUD and HIV (23, 24).  Aggressive 
control of chancroid, a prevalent and highly transmissible GUD, may have the potential 
to curtail the global spread of HIV (34, 37, 42).     
Chancroid presents as a painful genital ulcer with a ragged erythematous border.  
This lesion emits a purulent exudate replete with macrophages, neutrophils, T and B 
lymphocytes and bacteria (both H. ducreyi and other opportunistic species) (32).  H. 
ducreyi does not cause disseminated infection in healthy or immunocompromised 
individuals, and appears to be well-adapted to survive in the skin of its obligate human 
host (59).  However, the mechanism by which H. ducreyi colonizes skin remains poorly 
understood.  H. ducreyi attaches to the HaCaT keratinocyte cell line in vitro (62), and this 
association is dependent upon expression of the outer membrane protein DsrA (15).  
DsrA also confers resistance to complement-mediated killing by normal human serum 
(19).  H. ducreyi lacking DsrA is attenuated in both human and swine experimental 
chancroid models (12), but it is not clear how the keratinocyte attachment or serum 
resistance properties of DsrA specifically contribute to this phenotype.   H. ducreyi also 
adheres to human foreskin dermal fibroblasts and forms microcolonies in vitro; this 
aggregative-adhesive phenotype depends on expression of the fimbria-like protein 
encoded by the flp gene cluster (41).  Human volunteers inoculated with an flp mutant 
display lesions that fail to progress from papular to pustular stage, and live H. ducreyi was 
recovered from only 1 of 31 of these sites (53), suggesting that the above phenotype 
contributes to H. ducreyi survival in skin. 
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Despite the observation that H. ducreyi adheres to skin epithelial cells and 
fibroblasts in vitro, direct association between H. ducreyi and these types of cells within 
the chancroid lesion has not been proven.  H. ducreyi was, however, shown to bind the 
extracellular matrix (ECM) proteins fibronectin, laminin and collagen types I and III in 
vitro (9).  In early-stage lesions derived from the human challenge model, H. ducreyi 
colocalized with macrophages and neutrophils within the pustule and also associated with 
fibrin and collagen in the dermis directly beneath the pustule (8).  These findings suggest 
that adherence to ECM proteins, which comprise a major structural component of skin, 
may be an important contributing factor in H. ducreyi skin colonization. 
We recently found that protection against H. ducreyi infection in the swine model 
of chancroid coincides with the emergence of H. ducreyi-specific bactericidal serum 
antibodies, and that transfer of this immune serum protects naïve pigs against H. ducreyi 
challenge (16).  Antibodies present in this immune serum recognized a distinct subset of 
H. ducreyi outer membrane proteins.  Herein we describe one of these proteins, termed 
NcaA, and its role in mediating binding of H. ducreyi to collagen binding and in H. 
ducreyi pathogenesis. 
 
Materials and Methods 
 
Bacterial Growth Conditions. 
 H. ducreyi strains were grown on chocolate agar containing 1.5% Bacto agar, 2.5% 
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brain heart infusion (BHI), 1% bovine hemoglobin, 1% IsoVitaleX (Becton Dickinson, 
Cockeysville, MD), 5% newborn calf serum and 5% fetal bovine serum (Life 
Technologies, Inc., Rockville, MD) at 35°C in a humidified incubator with 5% CO2.  E. 
coli strains were propagated in LB broth or agar at 37°C.  Ampicillin, kanamycin, 
vancomycin, or chloramphenicol was added to media when indicated to a final 
concentration of 100, 40, 3, or 1 μg/ml respectively. 
 
Radioimmunoprecipitation of H. ducreyi outer membrane proteins. 
 H. ducreyi 35000HP was grown overnight on chocolate agar as a confluent lawn, 
harvested, and resuspended in PBS.  This suspension was added to a precoated IODO-
GEN tube (Pierce Biotechnology, Rockford, IL) with 1.0 mCi of 125NaI.  Labeling was 
quenched after 3 min with an excess of GCB broth.  Surface-iodinated bacteria were 
washed and mixed with preimmune or H. ducreyi-immune pig serum, incubated 15 min 
at RT with occasional mixing, again washed with PBS and pelleted.  The resulting cell 
pellet was then resuspended in RIP buffer (2% Zwittergent 3-14, 50 mM Tris pH 8.0, 5 
mM EDTA, 0.15 M NaCl) and incubated with rocking for 30 min at 37°C.  Insoluble 
matter was removed by centrifugation (5 min at 14,000 x g), and the supernatant 
containing solubilized antibody-labeled outer membranes was mixed with protein G 
agarose (Sigma Chemical, St. Louis, MO).  After overnight rocking at 4°C, the slurry was 
washed 3 times with RIP buffer and once with diH2O.  The resulting pellet was 
resuspended in Laemmli sample buffer containing β-mercaptoethanol, boiled, and 
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resolved by SDS-polyacrylamide gel electrophoresis.  Resolved bands of iodinated (outer 
membrane) proteins bound by preimmune or H. ducreyi-immune pig serum were 
visualized by autoradiography.   
 
Identification, cloning, and mutagenesis of ncaA. 
H. ducreyi outer membrane proteins were resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene 
difluoride (PVDF) membrane.  Protein bands were excised and subjected to Edman 
degradation by the UNC Protein Sequencing & Peptide Synthesis Facility (University of 
North Carolina, Chapel Hill, NC).    Amino acid sequences were compared using 
EMBOSS pairwise alignment algorithms hosted by the European Bioinformatics Institute. 
(http://www.ebi.ac.uk/emboss/align/index.html).  The ncaA gene was amplified by PCR 
from H. ducreyi 35000HP genomic DNA using forward primer 
5’CTAGGCTAATGAGAGGTATATCG3’ and reverse primer 
5’TTGTACGCATCGCTTGTTCC3’.  The resulting product was cloned into pCR2.1 
(Invitrogen, Carlsbad, CA) and was verified by automated DNA sequencing (UNC 
Genome Analysis Facility, Chapel Hill, NC).  To produce an inactivated allele of ncaA, a 
134 bp segment of ncaA between two Nde I sites was excised and replaced with a 
chloramphenicol acetyltransferase (cat) cassette derived from pUNCH40 (57).  The cat-
interrupted ncaA gene (ncaA::cat) was subcloned into plasmid pRSM2072 (gift of Robert 
S. Munson, Jr.) and the resulting construct was used as a suicide vector to perform allelic 
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exchange in H. ducreyi as described by Bozue et al. (14).  H. ducreyi 35000HP was 
transformed with pRSM2072-ncaA::cat and plated on chloramphenicol to select 
cointegrates.  Cointegrates were then plated on media containing chloramphenicol and 
X-gal (40 μg/ml) to counterselect for excision of the pRSM2072 vector backbone and the 
wild type ncaA allele.  Southern blot and PCR analysis of the mutant confirmed that a 
single copy of the cat cassette had been inserted into ncaA (data not shown).  
Transcription of genes adjacent to the ncaA locus (Fig. 3.1) in 35000HP and 
35000HPncaA was found equivalent by reverse transcriptase PCR, showing that ncaA 
inactivation did not exert a negative polar effect on local transcription.  To examine 
whether 35000HPncaA had phenotypes other than that caused by the mutation, 
35000HPncaA was compared to the master 35000HP stock used to infect human 
volunteers.  The phenotypes included comparisons of growth rates in broth, OMP and 
LOS profiles, as previously described (21).  35000HP and 35000HPncaA had similar 
generation times in broth (data not shown).  OMP and LOS from 35000HP and 
35000HPncaA were analyzed by SDS-PAGE, followed by Coomassie blue and silver 
staining.  The OMP and LOS profiles demonstrated no difference between the parent and 
the mutant (data not shown).  Because NcaA is a low abundance protein as determined 
by Coomassie blue staining, ablation of NcaA protein expression in the mutant strain was 
confirmed by Western blot analysis with H. ducreyi-immune pig serum (Fig. 3.2).  
Whole-cell lysates of 35000HP and 35000HPncaA were heated in sample buffer 
containing SDS and β-mercaptoethanol, then resolved by SDS-PAGE and blotted to 
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nitrocellulose.  The blot was probed with H. ducreyi-immune pig serum (1:1000) followed 
by peroxidase-conjugated rabbit-anti pig Ig (1:32,000; Sigma Chemical, St. Louis, MO) 
and chemiluminescent detection (SuperSignal Pico, Pierce Biotechnology, Rockford, IL).   
 
Serum Susceptibility Assay.  
Serum susceptibility assays were performed as previously described (19).  Briefly, 
bacteria grown on solid media for 16-18 hours were collected and suspended in 2 ml of 
BHI, vortexed for 5 seconds and allowed to settle for 5 minutes.  After settling, the upper 
1 ml was removed and the cell density was adjusted such that the final concentration of 
bacteria was approximately 1-5 x 103 CFU/ml.  Bacteria were mixed with fresh or heat-
inactivated normal swine serum to a final concentration of 25% or 50%.  Following 
incubation for 45 minutes (35°C, 5% CO2) the bacterial suspensions were plated to count 
viable CFU.  Percent survival was calculated by dividing the number of CFU from fresh 
serum by the number from heat-inactivated serum and multiplying by 100.  Assays were 
performed in triplicate and on three separate days.   
 
Fluorescein labeling of bacterial strains. 
 Overnight cultures of H. ducreyi grown on chocolate agar or E. coli grown in LB 
broth were collected and washed three times in phosphate-buffered saline (PBS) followed 
by passage through a 30-gauge needle to disperse large aggregates.  Carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE) (Molecular Probes, Eugene, OR) in DMSO was 
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added to a final concentration of 12 μM and the suspension was incubated with gentle 
mixing at 35°C for 25 minutes.  H. ducreyi labeling reactions were quenched with an 
equal volume of BHI media supplemented with 1% IsoVitaleX (Becton Dickinson, 
Cockeysville, MD), 1% hemoglobin, (Becton Dickinson, Cockeysville, MD), and 10% fetal 
bovine serum (Life Technologies, Rockville, MD).  E. coli labeling reactions were 
quenched by addition of BSA to a final concentration of 1%.  The resulting fluorescein-
labeled bacteria were collected by centrifugation at 1040 x g for 10 minutes and 
resuspended in LB (E. coli) or in BHI supplemented with 1% IsoVitaleX and 1% 
hemoglobin (H. ducreyi).  Bacteria were then incubated for 40-60 minutes at 35°C with 
shaking.  The doubling times of fluorescein-labeled and unlabeled H. ducreyi were similar 
(data not shown).     
 
Extracellular Matrix Protein Attachment Assay. 
 White 96-well plates (Fluoronunc, Nalge Nunc, Rochester, NY) were coated with 
bovine or human type I collagen (Chondrex, Redmond, WA), human cellular fibronectin 
or human plasma fibronectin (Sigma-Aldrich, St. Louis, MO) diluted in collagen dilution 
buffer (Chondrex, Redmond, WA) or 50 mM sodium carbonate pH 9.6 (fibronectins).  
Similar results were obtained in binding assays using bovine- and human-derived type I 
collagens.  Plates were incubated overnight at 35°C (fibronectin) or 4°C (collagen), 
washed three times with PBS containing 0.05% Tween-20 (PBST), and blocked with 300 
μl of 0.5% bovine serum albumin (Sigma-Aldrich, St. Louis, MO) in PBS for two hours at 
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35°C.  Wells were washed three times in PBS.  Fluorescein-labeled or non-labeled bacteria 
in BHI (200 μl) were added to appropriate wells.  Separate aliquots of the bacterial 
suspensions were serially diluted and plated to determine CFU input.  After 4 hours at 
35°C the wells were washed three times with PBST and 200 μl of PBS was added to all 
wells prior to reading fluorescence.  Fluorescence emission at 520 nm was measured 
following excitation at 490 nm using a microplate spectrometer (Model LS50B, Perkin 
Elmer Ltd., Beconsfield, Buckinghamshire, England).  Standard curves were established 
for each strain in each assay to allow calculation of attached CFU from fluorescence 
intensity.   
 
Animal Care.   
 Pigs were housed in an American Associated for Accreditation of Laboratory 
Animal Care-accredited P2 containment facility at North Carolina State University 
College of Veterinary Medicine.  Animals were sedated for all procedures with 0.3 ml per 
22.7 kg body weight of an anesthetic formulation consisting of:  Telazol (tiletamine HCl, 
50 mg/ml and zolazepam HCl, 50 mg/ml; Fort Dodge Laboratories, Fort Dodge, IA), 50 
mg/ml ketamine HCl (Fort Dodge Laboratories, Fort Dodge, IA) and 50 mg/ml xylazine 
(Miles Laboratories, Shawnee Mission, KS).  Atropine sulfate (Phoenix Scientific Inc., 
Joseph, MO) was given at 0.5 to 1 ml to slow salivary and bronchial secretion.  Pigs were 
maintained in the same room but in separate enclosures during the course of the study. 
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Virulence Testing in Pigs. 
 Inoculum preparation, inoculation and biopsy procedures were previously 
described (27, 50).  Briefly, H. ducreyi grown on chocolate agar was suspended in PBS and 
passed through a 30-gauge needle to disperse aggregates.  Multi-Test skin test applicators 
(Lincoln Diagnostics, Decatur Ill.) were loaded with 10 μl of inoculum and pressed into 
the dorsal side of the ear.  Each round of inoculations entailed 4 to 6 application sites per 
ear per strain tested.  Biopsies of experimental lesions collected two and seven days after 
inoculation using 6 mm skin biopsy punches (Acuderm, Ft. Lauderdale, FL) were minced 
and plated on chocolate agar containing vancomycin to detect viable H. ducreyi within 
lesions.  
 
Virulence Testing in Human Volunteers.   
 Healthy adult male and female volunteers over 18 years of age were recruited for 
the study.  Subjects gave informed consent for participation and for HIV serology, in 
accordance with the human experimentation guidelines of the U.S. Department of Health 
and Human Services and the Institutional Review Board of Indiana University-Purdue 
University of Indianapolis.  The experimental challenge protocol, preparation and 
inoculation of the bacteria, calculation of the estimated delivered dose (EDD), surface 
cultures and clinical observations were done exactly as described previously (4, 5, 54, 55, 
58).  Each subject was inoculated on one arm with 3 identical doses of the parent and on 
the other arm with 3 doses of twofold serial dilutions of the mutant.  Subjects were 
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observed until they reached a clinical endpoint, defined as either 14 days after 
inoculation, development of a pustule that was either painful or greater than 4 mm in 
diameter, or resolution of infection at all sites.  Once a clinical endpoint was achieved, the 
code was broken, and sites with clinical disease, if present, were biopsied.  The subjects 
were then treated with two doses of oral ciprofloxacin (5, 55). 
 To confirm that the inocula were correct and that no phenotypic changes 
occurred during infection, individual colonies from the inocula, surface cultures, and 
biopsy specimens were picked, suspended in freezing medium, and frozen in 96-well 
plates.  The colonies were scored for susceptibility to chloramphenicol.  If available, 
sufficient colonies (n > 30) from an individual specimen were scored so that there was a 
95% probability that < 11% of the colonies would have the incorrect phenotype (1). 
 
Statistical Analysis. 
 Data from the pig model were analyzed using SigmaStat version 2.0 (Jandel 
Scientific, San Rafael, CA) and SAS version 9 (SAS Institute Inc., Cary, NC).  Numbers of 
viable wild type and mutant H. ducreyi CFU recovered from lesion biopsies were analyzed 
using Poisson regression.  Percentages of biopsies culture-positive were analyzed via 
logistic regression modeling of probabilities of recovery.  Both regression models were 
adjusted for variability among pigs using generalized estimating equations (GEE).  
Comparisons of papule and pustule formation rates between the two strains in the human 
challenge model were performed using a logistic regression model using GEE to account 
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for the correlation among sites within the same subject, as described (53).  The GEE 
sandwich estimate for the standard errors was used to calculate 95% confidence intervals 
for these rates.  When a rate was zero, the exact binomial confidence intervals were 
calculated based on the number of subjects rather than the number of sites.  The z-
significance test of two means was used to compare the adherence of different strains of 
bacteria to type I collagen (Fig. 3), and the t-test was used to determine the significance of 
NcaA-expressing E. coli bound to collagen (Fig. 4).   
 
Results 
 
Identification of a putative oligomeric coiled adhesin in H. ducreyi . 
We recently demonstrated that pigs repeatedly inoculated with H. ducreyi develop 
a modest antibody-mediated protective response against reinfection (16).  Targets of this 
antibody response were identified by immunoprecipitation of 125I-labeled H. ducreyi outer 
membrane proteins (OMPs) using immune sera from multiply-inoculated pigs.  Seven 
distinct H. ducreyi outer membrane proteins were precipitated exclusively by immune 
sera (data not shown).  One of these proteins with an apparent molecular weight of >100 
kDa was isolated and identified via N-terminal amino acid sequencing and comparison to 
the published H. ducreyi genome sequence.  The N-terminal sequence, I T T E S I P T, 
matched predicted amino acids 21-28 of a previously uncharacterized H. ducreyi OMP 
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(hypothetical protein HD1920 BLAST accession NP_874254) with a predicted molecular 
weight of ~33 kDa.  We named this protein NcaA.  
 The NcaA amino acid sequence is similar to the H. ducreyi OMP DsrA (25.1% 
identity and 42.6% similarity), Yersinia enterocolitica YadA (23.0% identity and 39.9% 
similarity), Moraxella catarrhalis UspA proteins (21.0-22.0% identity and 35.6-39.3% 
similarity), and the Escherichia coli Eib proteins (20.7-27.2% identity and 38.0-43.2% 
similarity).  These proteins have been described as oligomeric coiled adhesins (Oca) (48), 
a subfamily of the type Vc surface-attached oligomeric autotransporter family (25).  They 
are typified by a signature C-terminal 9 amino acid stretch of alternating hydrophobic 
amino acids terminating with phenylalanine or tryptophan which comprises an outer 
membrane localization motif.  The C-terminal region of these proteins also appears to 
mediate the formation of multimers that can remain stable even when heated with 
detergent and reducing agents (48).  The disparity between the hypothetical molecular 
weight of monomeric NcaA and its dramatically slower migration in SDS-PAGE (Fig. 2) 
is consistent with similar proteins of this nature.  The sequence of the 79 C-terminal 
amino acids of NcaA is 98% similar to the consensus Oca sequence and also possesses the 
9 amino acid terminus motif.  Oca proteins, in addition to the C-terminal signature 
sequence, share other properties including involvement in adherence, binding of 
extracellular matrix (ECM) proteins, and resistance to complement-mediated killing.  
These common functions led us to investigate whether NcaA mediates adherence to 
eukaryotic cells and ECM proteins.   
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Extracellular Matrix Protein Binding Properties of NcaA.   
 To determine whether NcaA binds ECM proteins we compared the ECM-binding 
properties of wild type H. ducreyi 35000HP with a mutant unable to express NcaA due to 
insertion-deletion inactivation of the ncaA gene (Fig. 3.2).  Fluorescein-labeled 35000HP 
and the ncaA mutant (35000HPncaA) were incubated in ECM-coated microplate wells.  
Assays were performed by incubating a bacterial suspension of constant density in wells 
coated with a range of ECM concentrations from 0 to 80 μg/ml.  A minimum H. ducreyi 
density of 107 CFU/ml was sufficient to ensure that binding saturation was achieved at the 
highest ECM concentrations. Bacterial binding was determined by measuring the 
fluorescence intensity of each well following incubation and washing, then relating that 
intensity to an assay-specific standard curve correlating fluorescence to CFU.     
Binding of the ncaA mutant strain to type I human collagen was significantly less 
than that of its isogenic parent strain H. ducreyi 35000HP (Fig. 3.3) with statistically 
significant differences in attachment at all ECM concentrations tested except 0.002 μg/ml.  
In contrast, there was no difference in the level of binding of 35000HP or 35000HPncaA 
to heparin (an analog of the cell surface receptor heparan sulfate proteoglycan), plasma 
fibronectin, or cellular fibronectin (data not shown).  These data indicate that NcaA 
promotes specific adherence to type I collagen and not to related ECM proteins or cell 
surface adhesion molecules.   
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To determine if NcaA was sufficient to confer adherence to type I collagen, we 
tested the binding phenotype of E. coli expressing H. ducreyi NcaA.  E. coli TOP10 
containing the ncaA gene in pCR2.1 (TOP10 pncaA) or with pCR2.1 vector alone 
(TOP10 pCR2.1) were fluorescently labeled and incubated in microplate wells coated 
with type I collagen.    Approximately 106 TOP10 pncaA CFU bound to collagen 
following incubation with 8 x 106 CFU, whereas fewer than 100 TOP10 pCR2.1 CFU 
remained after incubation with 3.2 x 107 CFU (Fig. 3.4).  TOP10 pncaA did not bind wells 
coated with plasma fibronectin (data not shown).  These data indicate that NcaA is both 
necessary and sufficient to elicit specific association with type I collagen. 
 
Effect of NcaA expression on H. ducreyi serum resistance and adherence to 
keratinocytes and foreskin fibroblasts. 
 
 The Oca proteins UspA2, (2), YadA (7, 35) and Eib proteins A, C, D, E, and F (51, 
52) impart resistance in their respective organisms to complement-mediated killing in the 
absence of opsonizing antibody, and have also been shown to mediate binding to host 
receptors.  NcaA has significant amino acid sequence similarity to DsrA, an H. ducreyi 
outer membrane protein and Oca protein that confers resistance to killing by normal 
human serum (19) as well as attachment to keratinocytes (15).  We therefore tested the 
sensitivity of 35000HPncaA to normal human serum.  The serum-sensitive strain H. 
ducreyi FX517 (35000HPdsrA) was effectively killed by 25% and 50% naïve pig serum 
with complement, whereas 35000HP and 35000HPncaA were both resistant to 
complement-mediated killing (Fig. 3.5).  We also determined if NcaA mediates adhesion 
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to keratinocytes and fibroblasts, which are the predominant cell types in skin.  Both 
35000HP and 35000HPncaA adhered to HaCaT cells, a human keratinocyte cell line (13) 
and HS27 cells, a human foreskin fibroblast cell line (1634-C, American Type Culture 
Collection, Manassas, VA) (data not shown).  From these findings we concluded that 
NcaA neither contributes to serum resistance nor promotes adhesion to skin fibroblasts 
or keratinocytes in vitro. 
 
NcaA expression is necessary for virulence in the swine model of chancroid infection.   
 To determine if NcaA is important in skin lesion formation in vivo we inoculated 
pigs with 35000HP or 35000HPncaA and assessed bacterial recovery from biopsies taken 
two or seven days post-inoculation (p.i.).  These data were generated from 14 animals 
across 6 experimental iterations.  The percentage of biopsies containing viable H. ducreyi 
at day 2 p.i. was not significantly different between sites inoculated with 35000HP or 
35000HPncaA (60.3% versus 56.4% culture-positive, respectively; Table 3.1).  However 
there was a statistically significant difference (P < 0.0001) between the proportions of 
culture-positive biopsies taken at day 7 p.i. from sites inoculated with 35000HP (72.9%) 
or 35000HPncaA (20.0%).  Despite similar numbers of culture-positive biopsies at day 2 
p.i., the average number of CFU recovered from 35000HP-inoculated sites was over 5-
fold higher than the number recovered from mutant-inoculated sites (161.0 vs. 30.4 CFU 
per biopsy).  This span increased to over 24-fold at day 7 p.i. (146.8 vs. 6.1).  Differences 
in number of CFU recovered per biopsy were statistically significant (P < 0.0001) at both 
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days biopsied.  We also inoculated pigs with the cointegrate merodiploid strain generated 
during construction of 35000HPncaA in order to determine if the phenotype of 
35000HPncaA was due to a spurious attenuating mutation rather than the targeted 
inactivation of the ncaA locus.  Unlike 35000HPncaA, the cointegrate was recovered from 
pig ear lesions with similar frequency and in similar amounts to wild type 35000HP at 
days 2 and 7 p.i. (Table 3.1), demonstrating that this strain is not attenuated.   
 
Human inoculation experiments.   
 The human challenge model allowed us to assess the importance of NcaA in 
establishing infection in the natural host of H. ducreyi.  An escalating dose-response study 
was used to compare the virulence of 35000HP and 35000HPncaA.  Eleven healthy adults 
(seven females, four males; age range of 20 to 53; mean age + the standard deviation, 38.6 
+ 11.3) volunteered for the study.  One subject (245) withdrew prior to inoculation.  In 
the first iteration, one subject was inoculated at 3 sites with an EDD of 34 CFU of the 
parent and at three sites with EDDs of 23, 46, and 92 CFU of the mutant.  Papules 
developed at 2 of 3 sites inoculated with the parent and 2 of 3 sites inoculated with the 
mutant, but all the papules resolved (Table 3.2).  In the second iteration, 3 subjects were 
inoculated at 3 sites with an EDD of 85 CFU of the parent and at 3 sites with EDDs of 31, 
62, and 124 CFU of the mutant.  Papules developed at 4 of 9 sites inoculated with the 
parent strain and at 5 of 9 sites inoculated with the mutant (Table 3.2).  A pustule 
developed at 1 parent site while all mutant sites resolved (Table 3.2).  In the third 
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iteration, the subjects were inoculated with an EDD of 92 CFU of the parent and with 
EDDs of 74, 147, and 294 CFU of the mutant.  Papules developed at all 9 parent and at 7 
of 9 mutant sites (Table 3.2).  Pustules developed at 6 of 9 parent sites, while all mutant 
papules resolved.  In the fourth iteration, the subjects were inoculated with an EDD of 
140 CFU of the parent, and EDDs of 490, 960, and 1920 CFU of the mutant.  Papules 
developed at 8 of 9 sites inoculated with the parent and at 8 of 9 sites inoculated with the 
mutant (Table 3.2).  A pustule developed at 1 parent site, while all mutant sites resolved 
(Table 3.2).   
 The cumulative results for the four iterations showed that papules developed at 
76.7% (95% CI, 55.9%-97.4%) of sites inoculated with 35000HP and at 74.3% (95% CI, 
55.3%-91.3%) of sites inoculated with 35000HPncaA.  Overall, pustules formed at 8/30 
(26.7%; 95% CI, 6.4%-46.9%) sites inoculated with 35000HP compared to 0 of 30 (0%; 
95% CI, 0%-25.9%) sites inoculated with 35000HPncaA (P = 0.005).  Thus, the mutant 
was impaired in its ability to form pustules when compared to the parent.   
 For the four parent and four mutant broth cultures used to prepare the inocula, all 
192 parent colonies and all 192 mutant colonies tested were phenotypically correct 
(mutant, Cmr (chloramphenicol resistant); parent, Cms).  Of the 30 sites that were 
inoculated with the parent, 6 (20%) yielded at least one positive surface culture, while 0 of 
18 mutant sites yielded a positive surface culture.  All colonies obtained from surface 
cultures (n=346) and biopsy specimens (n=9) from parent sites were phenotypically 
correct (Cms).  Thus, all tested colonies from the inocula, surface cultures and biopsy 
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specimens had the expected phenotype.  We were unable to test the merodiploid strain 
for complementation of the 35000HPncaA phenotype because inoculation of human 
volunteers with strains that harbor plasmids is not permitted. 
 
Discussion 
 
 During the course of identifying targets of immune serum that conferred 
protection against H. ducreyi infection in the swine chancroid model, we found that at 
least one of the antibodies bound a previously uncharacterized outer membrane protein.   
We named this protein NcaA because our findings have shown it to be necessary for 
collagen association in H. ducreyi.  The sequence of the C-terminal 79 amino acids of 
NcaA is similar to that of the oligomeric coiled adhesin (Oca) subfamily of 
autotransporter proteins.  Oca proteins form oligomeric lollipop-shaped surface 
projections on the bacterial outer membrane consisting of N-terminal head and neck 
domains followed by a coiled-coil stalk and a YadA-like C-terminal domain that anchors 
the protein in the outer membrane (28, 48).  The amino acid sequence of NcaA is 
consistent with this proposed structure, but its three-dimensional structure has not been 
determined.  Oca proteins also migrate as heat-stable oligomers during SDS-PAGE.  This 
peculiarity is thought to reflect the avid oligomerization property of these proteins on the 
bacterial surface (3, 19, 36, 48, 52).  YadA exists as a trimer both when anchored to the 
bacterial outer membrane and during migration through SDS-PAGE (48).  Monomeric 
77 
NcaA has a predicted molecular mass of 33 kDa but shows an apparent size of >100 kDa 
in SDS-PAGE (Fig. 3.2), suggesting that it also oligomerizes, though it is not known how 
many NcaA monomers assemble to form a functional complex. 
 Chancroid transmission occurs when H. ducreyi penetrates the keratinized skin 
surface layer and colonizes the dermis or epidermis of the skin.  Type I collagen is the 
predominant structural component of skin (6) and H. ducreyi is found associated with 
type I collagen in the dermis of biopsy samples collected from human volunteers 48 hours 
post-inoculation (8).  Other ECM attachment studies also demonstrated that H. ducreyi 
binds to immobilized type I collagen in vitro (1, 9).  Our results indicate that specific 
association of H. ducreyi with type I collagen is mediated by NcaA.  Collagen binding is a 
crucial factor in the pathogenesis of other organisms that inhabit skin during infection.   
For example, loss of YadA-mediated collagen binding is associated with loss of Yersinia 
enterocolitica virulence in a mouse model of infection (56).  In addition, the 
Staphylococcus aureus collagen adhesin Cna is required for virulence in multiple animal 
models of infection (18, 26, 44, 46).  Our finding that NcaA binds collagen is consistent 
with the nature of H. ducreyi as a dermal pathogen.   
Our in vitro experiments showed that NcaA neither mediates adherence to 
cultured skin cells nor confers resistance to complement-mediated killing.  We also 
demonstrated that NcaA is necessary and sufficient for bacterial association with type I 
collagen.  Bacterial adherence to host tissues is generally considered to be an essential step 
in establishing infection (10, 43).  Our studies here illustrate that adhesins mediating 
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association of bacteria with structural ECM proteins in contrast to adherence to host cells 
can also be important virulence determinants.   NcaA appears to have such a role in H. 
ducreyi pathogenesis.  In pigs, the ncaA mutant was recovered from significantly fewer 
lesions than wild type.  In human volunteers, the ncaA mutant was unable to form 
pustules, making NcaA the seventh H. ducreyi protein shown to be essential for virulence 
in the native human host (4, 12, 21, 29, 53).  Whereas these findings demonstrate that 
NcaA is required for infection of humans and pigs, we are conducting further studies to 
elucidate the collagen binding property of NcaA and to determine whether it is directly 
responsible for the contribution of NcaA to H. ducreyi pathogenesis.  We are also 
determining if an antibody response against NcaA can confer protection against H. 
ducreyi infection. 
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Table 3.2.  Human volunteer response to inoculation of live H. ducreyi strainsa 
Final Outcome of Initial Papule
Volunteer Genderb 
Days of 
Observation 
Strain No. of Initial 
Papules No. Pustules No. Resolved 
35000HP 2  2 244 F 5 
35000HPncaA 2  2 
35000HP 3 1 2 
243 F 9 
35000HPncaA 2  2 
35000HP 1  1 
247 M 3 
35000HPncaA 0   
35000HP 0   
248 F 5 
35000HPncaA 2  2 
35000HP 3 1 2 
249 M 8 
35000HPncaA 2  2 
35000HP 3 3  
250 F 7 
35000HPncaA 3  3 
35000HP 3 2 1 
251 M 8 
35000HPncaA 3  3 
35000HP 3  3 
242 F 6 
35000HPncaA 3  3 
35000HP 3 1, c 1 
252 F 9 
35000HPncaA 3  3 
35000HP 2  2 
253 F 5 
35000HPncaA 2  2 
aVolunteer 244 was inoculated in iteration #1. Volunteers 243, 247 and 248 were inoculated in iteration #2. 
Volunteers 249, 250, and 251 were inoculated in iteration #3. Volunteers 242, 252, and 253 were inoculated 
in iteration #4.   
b M, male; F, female.   
cOne site remained a papule at the time the subject achieved endpoint.   
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Figure 3.1.  The H. ducreyi 35000HP ncaA locus and neighboring genes.   
RNA transcripts of prolyl tRNA ligase (proS, HD1919), ATP-dependent DNA helicase 
(recG, HD1921), and RNA polymerase ω subunit (rpoZ, HD1923) were detected by RT-
PCR and found to be produced in both 35000HP and 35000HPncaA (in which the ncaA 
gene is insertionally inactivated by cat as shown). 
ncaAproS recG rpoZ
135 bp 109 bp 119 bp
1.7 kb 0.9 kb 2.2 kb 0.3 kb
cat
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Figure 3.2.  Immunoblot of H. ducreyi 35000HP (wt) and 35000HPncaA (ncaA-) whole 
cell lysates using immune pig serum.   
Arrow indicates the position of an apparently multimeric form of NcaA, which migrated 
as a >100 kDa protein despite heating in the presence of SDS and β-mercaptoethanol.  
Other bands represent the constellation of H. ducreyi proteins recognized by polyclonal 
immune pig serum.  Numbers indicate molecular weight standards in kilodaltons.  The 
immunoblot film was scanned with an HP ScanJet 3970.  The contrast of the scanned 
image was adjusted using the auto contrast command within Adobe Photoshop CS, and 
annotations were added with Adobe Illustrator CS.
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Figure 3.3.  Adherence of fluorescently labeled ncaA mutant (grey plot) or wild type 
(black dashed plot) H. ducreyi to immobilized type I collagen.   
Adherence at each concentration of collagen was tested eight times in each assay and 
adherence assays were performed three times for each strain.  Data presented were 
averaged from the three assays and error bars depict ± SEM.  All values except the lowest 
(0.002 μg/mL collagen) were significantly different (all P < 0.05). 
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Figure 3.4.  Impact of NcaA expression on E. coli adherence to type I collagen.   
Fluorescently labeled E. coli TOP10 containing empty vector or ncaA plasmids were 
incubated in microplate wells coated with 40 μg/ml bovine type I collagen.  Data 
presented are mean E. coli CFU bound (error bars show ± SEM) following incubation 
with 1.6 x 107 and 8.0 x 106 vector or ncaA containing CFU respectively. 
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Figure 3.5.  Serum sensitivity of H. ducreyi mutants.   
Survival of wild type (black bars), ncaA mutant (white bars), and dsrA mutant (grey bars) 
H. ducreyi after incubation in 25% or 50% normal pig serum.  Serum survival was assayed 
in triplicate in three independent experiments (error bars show ± SEM). 
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 Chancroid is a genital ulcer disease that is associated with increased risk of HIV 
transmission and acquisition.  It is caused by the gram-negative bacterium Haemophilus 
ducreyi, and infection with H. ducreyi does not elicit protective immunity.  H. ducreyi 
expresses cytolethal distending toxin (CDT), a soluble tripartite (CdtABC) protein 
complex that intoxicates and kills a range of eukaryotic cell types including some 
involved in host immunity.  We predicted that CDT is important for H. ducreyi virulence 
and may serve to modulate host immunity.  To test this hypothesis we generated H. 
ducreyi mutants unable to express the three CDT subunits (ΔcdtABC), tested soluble 
CDT activity in a cell culture system, and tested virulence in an experimental pig model 
of chancroid.  These ΔcdtABC strains generated culture supernatants non-toxic to HaCaT 
cells in vitro, and were highly attenuated in pigs.  However, the virulence of the ΔcdtABC 
strains within the pig model was not restored by cis- or trans-complementation with wild 
type cdtABC.  Thus, these results support but do not prove the essentiality of CDT to H. 
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ducreyi virulence in pigs.  In addition, repeated inoculation with cdtABC-null strains did 
not protect pigs against subsequent wild type challenge, suggesting that the absence of 
CDT during H. ducreyi infection does not lead to increased immunity to later challenge, 
and that CDT is not an immune modulator.  We also examined the role of nuclease 
activity in CDT toxicity by testing CdtB amino acid variants designed to lack DNase 
activity.  Supernatants from H. ducreyi strains expressing double-mutant CdtB (CdtB 
H160A, D199A; dmCdtB) maintained CDT toxicity against cultured cells, and 
recombinant purified dmCdtB digested plasmid DNA in vitro.  The fact that amino acid-
substituted CdtB variants retained activity demonstrates plasticity the in active site amino 
acid requirements for CdtB nuclease activity, but does not exclude or confirm nuclease 
activity as the primary means of CdtB-mediated toxicity.   
 
Introduction 
 
Haemophilus ducreyi, the causative agent of the genital ulcer disease (GUD) 
chancroid, is rare in developed nations but endemic in impoverished tropical regions of 
Africa, Asia, Latin America, and the Caribbean (37).  Studies show that GUD, including 
chancroid (27), facilitate transmission of other sexually transmitted infections, including 
human immunodeficiency virus, or HIV (8, 41).  Given the geographical overlap of 
chancroid and HIV and the established synergistic relationship between the two 
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pathogens (52) curtailment of chancroid is an important step in controlling the spread of 
HIV.   
A primary concern with global management of chancroid is that infected 
individuals fail to develop protective immunity following infection (6, 25).  This property 
allowed Auguste Ducrey in the late 1800s to initially characterize H. ducreyi by 
inoculating chancroid patients’ forearm skin with exudate from their ulcers, and 
repassaging matter from the resulting lesions for as many as 15 iterations (15, 16).  
Humans with naturally-acquired chancroid generate H. ducreyi-specific antibodies that 
increase in titer over prolonged infection, but there has been no correlation of antibody 
titer and protection against reinfection (2, 14, 38).  Furthermore, human H.ducreyi-
immune sera are not effectively bactericidal against H. ducreyi in vitro (22).  In an 
experimental model of chancroid, pigs repeatedly inoculated with the same H. ducreyi 
strain mounted a humoral response, though modest in titer and in efficacy upon passive 
transfer of immune sera to naïve animals (9, 26).  Similarly, human volunteers inoculated 
with H. ducreyi remain susceptible to rechallenge with the same strain (4).  Such 
experimental infections do not accurately represent the successive encounter of different 
strains as in natural infection but do create a scenario for the potential development of 
protective immunity to chancroid.  Failure of H. ducreyi exposure to elicit a protective 
humoral response of high titer even under successive experimental challenge with 
homologous strains suggests that H. ducreyi may actively evade or modulate the host 
immune response.  Immune evasion mediated by H. ducreyi could enhance its survival in 
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the host and thereby increase odds of transmission—an important quality for an obligate 
human pathogen.  Extension of such immunomodulation to other bystander pathogens 
may also explain the increased susceptibility of chancroid-infected persons to other STI.   
Among the factors mediating H. ducreyi virulence against eukaryotic cells is 
cytolethal distending toxin (CDT).  This toxin is so named because CDT-intoxicated cells 
undergo cell cycle arrest but continue to grow, often developing a characteristic distended 
morphology before ultimately undergoing apoptotic cell death (12, 21).  CDT is expressed 
by a host of pathogenic gram-negative bacterial species, including Haemophilus, 
Actinobacillus, Campylobacter, Shigella, Escherichia, and Salmonella.  Encoded by the 
cdtABC locus, the H. ducreyi CdtA, CdtB, and CdtC proteins assemble to form a tripartite 
holotoxin complex that is lethal to a wide range of eukaryotic cells including 
keratinocytes, endothelial cells, and fibroblasts, which are all present within the dermal 
locale of the chancroid lesion (10, 11).  In this manner, H. ducreyi CDT may contribute to 
lesion formation or persistence by killing the cells responsible for skin maintenance and 
repair (48).  CDT can also intoxicate cells relevant to immune function such as 
lymphocytes, macrophages, and dendritic cells (44, 46, 49).  An “immunosuppressive 
factor” discovered in the periodontal disease pathogen Actinobacillus 
actinomycetemcomitans that kills T and B lymphocytes and macrophages was later shown 
to be CDT (45).  However, direct evidence for immune cell toxicity of H. ducreyi CDT 
within the host has not been demonstrated. 
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Though it is clear that all three Cdt subunits are required for full CDT toxicity, 
CdtB is widely acknowledged to be the primary toxigenic subunit of the CDT holotoxin 
(13, 23, 32, 34, 47).  CdtB shares significant structural homology with bovine 
deoxyribonuclease (DNase) I, and recombinant H. ducreyi CdtB has been shown to 
mediate scission of double-stranded DNA in vitro (39).  Toxicity and in vitro DNase 
activity were reduced or neutralized in recombinant H. ducreyi (39), C. jejuni (31), and E. 
coli (19) CdtB variants in which amino acids homologous to critical catalytic or metal-
binding residues of DNase I activity were changed.    Furthermore, introduction of 
recombinant CdtB alone into the cytoplasm of eukaryotic cells recapitulates 
cytopathology seen in holotoxin-exposed cells (31, 35, 36).  Although these findings 
demonstrate a strong link between CdtB nuclease activity and CDT cytotoxicity, it has 
not been established whether CdtB-associated genotoxicity is the sole toxic determinant 
of CDT natively expressed by the bacterial pathogen.   
Despite the obvious cytotoxic properties of CDT, studies in a human experimental 
model of chancroid demonstrated that CDT is not essential for infection (54).  However, 
this study employed H. ducreyi 35000.303, a cdtC deletion mutant that expresses CdtA 
and CdtB, but culture supernatant from this strain lacked CDT activity (47).  Though it 
has not been shown whether this strain secretes CdtA and CdtB in the absence of CdtC 
expression, CdtC is required for assembly of fully active CDT holotoxin (39, 43).  The 
ability of 35000.303 to express CdtB brings into question the complete absence of CDT 
toxicity, since it is possible that CdtB is released upon lysis or uptake of H. ducreyi by 
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macrophages or dendritic cells, where the putative membrane binding or internalization 
functions of CdtA and CdtC may not be required.  This concern is further supported by 
the more recent finding that a strain of Salmonella enterica Typhi that does not carry cdtA 
or cdtC genes secretes a CdtB homolog via a sec-dependent pathway upon engulfment of 
bacteria by epithelial cells (24); in this strain, CdtB alone was sufficient to intoxicate 
eukaryotic cells.   
We propose that the most stringent test of the contribution of CDT to H. ducreyi 
pathogenesis is to assess the virulence of an H. ducreyi strain lacking all three CDT 
components.  Further, we hypothesize that CDT-deficient H. ducreyi will be attenuated, 
and may evoke a stronger protective immune response in the host following repeated 
inoculation in the absence of CDT-mediated immune modulation.  To test these 
hypotheses we constructed a cdtABC-deficient H. ducreyi strain and characterized its 
virulence in both in vitro assays and an in vivo model of H. ducreyi infection.  In addition, 
we investigated whether DNase activity is the sole or primary mode of CDT-mediated 
cytotoxicity by testing the activity of CdtB mutants in which residues predicted to be 
essential for DNase activity were altered. 
 
Materials and Methods 
 
Growth of bacterial cultures. 
 Haemophilus ducreyi cultures were grown on chocolate agar (25 g/L brain heart 
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infusion [BD, Franklin Lakes, NJ], 10 g/L freeze-dried hemoglobin [MP Biomedicals, 
Solon, OH], 1% IsoVitaleX [BD], 5% fetal calf serum [Sigma-Aldrich, St. Louis, MO or 
Gibco-Invitrogen, Grand Island, NY], 5% newborn calf serum [Gibco-Invitrogen], and 
1.5% agar) or in complete BHI broth (37 g/L brain heart infusion, 50 μg/mL hemin 
[Sigma-Aldrich], 1% IsoVitaleX, and 10% fetal calf serum).  Antibiotics were included as 
indicated:  10 μg/mL chloramphenicol (Cm), 30 μg/mL kanamycin (Kn), 3 μg/mL 
vancomycin (Vc) [all Sigma-Aldrich].  Escherichia coli cultures were grown in LB broth 
consisting of 10 g/L tryptone, 5 g/L yeast extract [BD], and 10 g/L NaCl, or on LB agar 
comprised of LB broth with 15 g/L agar [USB].  Antibiotics were included as indicated:  
100 μg/mL ampicillin (Ap), 35 μg/mL chloramphenicol (Cm), 40 μg/mL kanamycin (Kn).  
Recovery medium for E. coli and H. ducreyi electroporation (SOC) consisted of 20 g/L 
tryptone, 5 g/L yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
and 20 mM glucose. 
 
Mutagenesis of the H. ducreyi cdtABC locus. 
  H. ducreyi ΔcdtABC mutant ΔCDT1 was constructed by single-step, double-
crossover allelic exchange.  The mutagenesis construct was a linear DNA segment 
consisting of a chloramphenicol resistance (CmR) gene placed within the flanking 
sequence of the wild type cdtABC locus.  The chloramphenicol acetyltransferase (cat) 
cassette of pUNCH40 (51) was first isolated by Bgl II digestion.  Next, a 4.2 kb region of 
the H. ducreyi 35000 genome centered on the 2.2 kb cdtABC locus was amplified by PCR 
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using primers HdOSU720F and HdOSU720R.  This product was cloned into pCR2.1-
TOPO [Invitrogen] to produce pRAF30.  pRAF30 was digested with Nde I (190 bp 
upstream of cdtA start site) and SgrA I (18 bp upstream of the cdtC stop codon) to 
remove the cdtABC locus.  The Nde I/SgrA I-digested pRAF30 backbone and the cat 
cassette insert were blunt-ended with Klenow polymerase [New England Biolabs, 
Ipswich, MA] and ligated to create pRAF31.  The cdt-flanked cat cassette was digested 
from the pRAF31 backbone with Kpn I and Xho I, gel purified on 1% agarose-TAE and 
electroporated into H. ducreyi 35000 as linear DNA.  Bacteria grown overnight on 
chocolate agar were swabbed into cBHI and used to inoculate a 60 mL of cBHI to a 
turbidity of 40 as measured on a Klett-Summerson photoelectric colorimeter.  The 
culture was grown at 35°C for 2 h (Klett = 90) and harvested by centrifugation (5 min, 
1000 x g, RT).  Pellets were washed 4 times with 1 mL 10% glycerol and resuspended in 
100 μL 10% glycerol and held on ice.  Electroporated (2.5 kV, 25 μF, 200 Ω) bacteria were 
rescued in 900 μL SOC, then added to 4 mL of non-selective cBHI and grown for 2 h at 
35°C.  The culture was pelleted and plated on chocolate agar containing 1 μg/mL Cm; this 
selection yielded the CmR CDT-null mutant ΔCDT1.  Strain ΔCDT1 was complemented 
by transforming with  intact circular pRAF30 and plating on chocolate agar containing 1 
μg/mL Cm and 10 μg/mL Kn to select both the mutant ΔcdtABCcat allele and 
integration of the pRAF30 backbone.  The resulting merodiploid clone was designated 
ΔCDT1mero.   
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 A second H. ducreyi ΔcdtABC::cat mutant was created using a two-step allelic 
exchange procedure involving counterselection against the β-galactosidase (lacZ) gene as 
previously described (7).  First, the cdt-flanked cat cassette was PCR-amplified from 
pRAF31 [PfuTurbo, Stratagene, La Jolla, CA] using the HdOSU730F/R primer pair.  
Suicide vector pRSM2072 (7) was digested with Xho I, blunt-ended with Klenow 
polymerase, and ligated with cdt-flanked cat to form pRAF101.  H. ducreyi 35000 was 
transformed with circular pRAF101 and plated on chocolate agar with 1 μg/mL Cm.  H. 
ducreyi isolates expressing lacZ (carried by pRSM2072) grow slowly on media with X-gal 
[5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside], allowing counterselection for 
plasmid cointegrate excision (7).  pRAF101 transformants were streaked on chocolate 
agar containing 1 μg/mL Cm and 40 μg/mL X-gal, and relatively fast-growing, white-
colored colonies were chosen yielding the ΔcdtABC::cat mutant ΔCDT2.  The mutant 
cdtABCcat allele of ΔCDT2 was replaced with wild type cdtABC using the same two-
step procedure, using pRAF100K as the donor for allelic exchange.  Transformants were 
selected on 1 μg/mL Cm and 10 μg/mL Kn and counterselected on chocolate agar with 40 
μg/mL X-gal and no antibiotics.  Fast-growing white colonies were patched onto fresh 
medium, tested for Kn- and Cm-sensitive phenotypes, and screened using the methods 
mentioned below.  The final wild type “repaired” strain was named ΔCDT2rep.   
 An H. ducreyi 35000 mutant expressing an altered “double-mutant” (His 160 to 
Ala, Asp 199 to Ala) CdtB was also created by the two-step procedure outlined above.  
The allelic exchange construct was created by performing two stepwise QuikChange II XL 
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[Stratagene] reactions on pRAF100K, first with the primer pair HdCdtB(H160A)F/R, 
then with primer pair HdCdtB(D199A)F/R.  The resulting pRAF100KBdm was used for 
two-step allelic exchange with wild type cdtB in H. ducreyi 35000.  Following X-gal 
counterselection, clones were screened by amplifying the cdtABC locus by PCR 
(CdtSeqF1/R1 primers) and digesting the amplicon to test for a novel Bsm I site 
introduced by the H160A substitution.  Because the double-mutant cdtB allele was 
unmarked, some isolates resolved of pRAF100KBdm carried the double-mutant allele, 
and some reverted to wild type.  One isolate of each genotype was carried forward:  strain 
DMB (double-mutant cdtB) and strain WTB (wild type cdtB).   
 The genotypes of H. ducreyi cdt mutants were confirmed by Southern blot 
analysis and DNA sequencing [UNC Genomic Analysis Facility, Chapel Hill, NC] using 
the Hd35kCDT+flankF/R primers (Table 2).  Genotypes were further analyzed by 
Southern blotting.  Genomic DNA isolated [MasterPure DNA purification kit, Epicentre 
Biotechnologies, Madison, WI] from H. ducreyi strains was digested with Pst I and 
resolved on 0.8% agarose-TAE, blotted to a nylon membrane [Hybond-N+, GE 
Healthcare, Piscataway, NJ] using capillary transfer, and UV-crosslinked [Stratalinker, 
Stratagene].  Digoxigenin (DIG)-labeled PCR products [PCR DIG Probe Synthesis Kit, 
Roche, Indianapolis, IN] corresponding to the cdtB gene (primers cdtB-BamHI-F/EcoRI-
R, template pRAF30) or the cat gene (primers cdt_flank_F/R, template pRAF31) were 
generated and used to probe the blotted DNA fragments.  Standard protocol for Southern 
blot hybridization was followed (5).  The blot was probed with peroxidase-conjugated α-
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DIG antibody, incubated with chemiluminescent substrate [Roche], and visualized by 
autoradiography  [HyBlot CL, Denville Scientific, Metuchen, NJ]. 
For analysis of CDT subunit expression, whole-cell suspensions of H. ducreyi 
strains were dispersed in 1x reducing SDS-PAGE loading buffer and resolved on 12.5% 
tris-glycine acrylamide gel.  Resolved proteins were transferred to supported 
nitrocellulose [Optitran BA-S 83, Whatman, Florham Park, NJ].  Membranes were 
blocked with 1% BSA in PBS-T (phosphate buffered saline plus 0.05% Tween-20), and 
probed with hybridoma supernatants containing mAb 1G8 (α-CdtA), 20B2 (α-CdtB), or 
8C9 (α-CdtC) [mAbs kind gift of Eric Hansen, University of Texas-Southwestern Medical 
Center, Dallas, TX], followed by peroxidase-conjugated α-mouse IgG [Sigma].  Blots were 
developed with chemiluminescent substrate [SuperSignal Pico, Pierce, Rockford, IL] and 
exposed to autoradiography film.   
 
Experimental inoculation of pigs with ΔCDT variants of H. ducreyi. 
 H. ducreyi strains were streaked onto chocolate agar for a confluent growth and 
incubated for 11-12 h at 35°C in 5% CO2.  The lawn was then restreaked onto 6 fresh 
plates and incubated for 12 h.  Antibiotics were included for plasmid maintenance where 
indicated.  Bacteria were collected and resuspended in 2 mL PBS with vortexing.  The 
suspension was forced through a 30G ½” needle to disperse aggregates.  Inoculum density 
was determined by serial dilution and culture on chocolate agar. 
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 Pigs were anesthetized using 0.3 mL/kg body weight of an anesthetic-analgesic 
solution injected intramuscularly.  The agent consisted of tiletamine HCl and zolazepam 
HCl 50 mg/mL each [Telazol, Fort Dodge Labs, Fort Dodge, IA], ketamine 50 mg/mL 
[Ketaset, Fort Dodge], and xylazine 50 mg/mL [TranquiVed, Miles Labs, Shawnee 
Mission, KS].  Ears were prepared by briefly but vigorously scrubbing the dorsal surface 
with a gauze pad moistened with water and 70% ethanol.  Bacterial inoculum (10 μL) was 
loaded onto the tines of a Multi-Test applicator [Lincoln Diagnostics, Decatur, IL] and 
pressed into the cleaned ear surface.  Sites were circled using Sharpie markers [Sanford 
Corporation, Oak Brook, IL] and photographed to record site inoculum and position.  
Subsets of lesions were biopsied at 2 and 7 days post-inoculation using 6 mm diameter 
biopsy punches [Acuderm, Ft. Lauderdale, FL] and longitudinally bisected.  Half was 
stored in complete BHI medium and half in 4% paraformaldehyde [Polysciences, 
Warrington, PA] in PBS.  Biopsies in BHI were minced and a defined quantity plated 
(usually 2 x 200 μL) on BHI + VCN for recovery.  After 48h incubation, H. ducreyi 
colonies were counted to record viable bacteria remaining in the experimental lesion at 2 
and 7 days following inoculation; these data were used as a measure of virulence of the 
tested strains. 
 
In vitro expression of CdtB variants. 
 Using QuikChange II XL [Stratagene] mutagenesis as described earlier, mutations 
encoding CdtB H160A and D199A substitutions were introduced into pRAF30 and into 
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pLSCDT, a derivative of H. ducreyi replicative plasmid pLS88 containing the wild type 
cdtABC locus.  These reactions produced the double-mutant cdtB constructs 
pRAF30dmB and pLSCDTdmB.  pLSCDTdmB was further mutagenized to encode a 
CdtB H274A substitution (using the primer pair HdCdtB(H274A)F/R) produce the 
“triple-mutant” cdtB construct pLSCDTtmB.  Wild type and double- or triple-mutant 
variants of cdtB were amplified using the primers cdtB-BamHI-F and cdtB-EcoRI-R.  
Wild type cdtB was amplified from pRAF30, whereas double- and triple- mutant cdtB 
were amplified from pLSCDTdmB and pLSCDTtmB, respectively.  PCR products were 
digested with BamH I and EcoR I and directionally ligated into pRSET A [Invitrogen], an 
N-terminal hexahistidine fusion protein expression vector.  The resulting plasmids 
pRAF21mat (wild type CdtB), pRSETdmB (H160A/D199A), and pRSETtmB 
(H160A/D199A/H274A) were maintained in TOP10 E. coli, and transformed into 
BL21(DE3)pLysS E. coli for protein expression. 
 Recombinant CdtB expression conditions were based closely on those by Deng et 
al. (13).  Overnight cultures of pRAF21mat, pRSETdmB, and pRSETtmB were grown in 
LB with 100 μg/mL Ap and 35 μg/mL Cm, diluted 1:25 into 250 mL LB with 100 μg/mL 
Ap and 2% glucose, and incubated with vigorous shaking at 37°C until the OD600 reached 
0.6-0.7.  Once cooled to RT, the culture was induced with 0.5 mM IPTG for 3-4 h and the 
bacteria were harvested by centrifugation (15 min, 8000 x g, 4°C) and stored at -80°C.  
After thawing, pellets were resuspended in 5 mL His purification buffer (HPB; 0.5 M 
NaCl, 5 mM imidazole in 20 mM Tris pH 8.0) with protease inhibitor [Complete Mini 
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protease inhibitor tablets; Roche] then freeze-thawed three times in dry ice-EtOH, then 
cold tap water.  The suspension was sonicated intermittently on wet ice and centrifuged at 
10,000 x g for 10 min at 4°C.  Ni2+-NTA agarose [Qiagen] was added to the clarified 
supernatant and mixed for 1 h at RT.  The slurry was loaded into a 1 mL column then 
washed and eluted with HPB containing escalating concentrations of imidazole; CdtB 
typically eluted at 80 mM imidazole.  Samples of each fraction were resolved by SDS-
PAGE and visualized with Coomassie Brilliant Blue R-250.  Fractions containing CdtB 
were pooled, dialyzed to remove imidazole and stored at 4°C.  Concentrations of purified 
recombinant CdtB variants were determined by BCA protein assay [Pierce]. 
 
In vitro cytotoxicity testing of H. ducreyi culture supernatants. 
 Complete BHI broth with 25 μg/mL hemin but no serum or antibiotics was 
inoculated with H. ducreyi strains from glycerol freezer stocks and incubated for 18 h at 
35°C.  Routinely a loopful of each culture was streaked for isolation onto chocolate agar 
to test for contamination; in later cultures, high turbidity alone was used as indication of 
contamination (saturated H. ducreyi cultures have relatively low turbidity).  Cultures 
were centrifuged to remove bacteria (8000 x g, 15 min, 4°C) then these supernatants were 
ultracentrifuged to remove residual bacterial fragments (150,000 x g, 2 h, 4°C).  After 
filtration through 0.2 μm filters, supernatants were aliquoted and stored at -80°C; stability 
has been reported at 1 month (47), but our findings suggest a two-month maximum. 
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HaCaT cells were cultured in RPMI 1640 medium containing 10% fetal calf 
serum, β-mercaptoethanol, and 10 mM HEPES.  Cells were seeded at low (20-30%) 
confluency in tissue culture plasticware according to the analysis method.  For visual 
analysis, cells were cultured in clear flat-bottom 96-well microplates, or in 8-well chamber 
slides [Nalge Nunc, Rochester, NY].  For measurement of metabolic activity, cells were 
cultured in opaque white 96-well microplates [Corning, Acton, MA].  Cells were 
incubated overnight to allow recovery from passage and adherence. 
 An equal volume of supernatant was added to the tissue culture medium 
contained in each well to a total of 50% concentration.  For titration experiments, the 
supernatant was diluted in complete BHI and then added as above.  Each well was then 
washed twice with PBS, replenished with fresh culture medium, and incubated for 2 to 4 
hours at 37°C in 5% CO2.  Cells were observed or assayed at 24-48 hours post-
intoxication for CDT-associated cytopathology.  Controls included complete BHI, and 
untreated cells.   
 Visual analysis of CDT intoxication consisted of qualitative observation of cell 
morphology; CDT-intoxicated cells appear distinctly enlarged relative to untreated cells.  
For quantitative analysis of intoxication, the fluorescent metabolic indicator dye 
AlamarBlue [Biosource-Invitrogen, Carlsbad, CA] was added at 10% concentration to 
each well and incubated for 2-6 h.  Fluorescence from each well at 590 nm was measured 
during excitation at 530 nm using a BioTek Synergy HT [Winooski, VT] or Molecular 
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Devices SpectraMAX m2 [Sunnyvale, CA] microplate fluorimeter, with excitation and 
detection at the top of the wells.   
 
Assessing nuclease activity of recombinant CdtB proteins. 
 Defined quantities of purified recombinant wild type CdtB, dmCdtB, and tmCdtB 
were added to a reaction mixture consisting of 5 mM MgCl2, 0.4 μg/mL bovine serum 
albumin, 75 mM HEPES, and 0.5 μg of pUC19 [Invitrogen] plasmid DNA substrate.  Two 
control reactions were run in parallel:  one including buffer and DNA, but no protein, 
and one including recombinant purified β-galactosidase (LacZ) purified in parallel with 
CdtB variants to insure exclusion of E. coli nuclease activity during nickel-affinity 
purification.  Reactions were incubated at 37°C for 4 hours and were resolved by 
electrophoresis through 1% TAE-buffered agarose.  DNA species were stained with 
ethidium bromide and visualized and photographed under UV transillumination.  
Nuclease activity was qualitatively measured by the conversion of fast-migrating 
supercoiled plasmid to slow-migrating nicked or relaxed form or intermediate-migrating 
linear form.   
 
Results 
 
Construction and validation of H. ducreyi CDT deletion mutants. 
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To determine the influence of CDT on H. ducreyi virulence, we constructed 
mutants unable to express the three CDT subunits by targeted allelic exchange.  The 
cdtABC locus of H. ducreyi wild type strain 35000 was exchanged in one double-crossover 
event with a chloramphenicol acetyltransferase (cat) gene to produce strain ΔCDT1.  The 
mutation in  ΔCDT1 was complemented in cis by chromosomal integration of a plasmid-
borne copy of cdtABC to produce ΔCDT1mero.  A second cdtABC-deletion mutant, 
ΔCDT2, was created by integration and resolution of the ΔcdtABCcat allelic exchange 
construct pRAF101 (7).  The cdtABC locus of strain ΔCDT2 was then restored to wild 
type allele using the same two-step procedure to produce the “repaired” strain 
ΔCDT2rep.    
H. ducreyi mutant strains ΔCDT1 and ΔCDT1mero were analyzed by Southern 
blot to rule out multiple integration of the ΔcdtABC::cat allele or other aberrant 
rearrangement.  A DIG-cdtB probe hybridized with a 4.7 kb fragment of Pvu I-digested 
35000 gDNA and a 6.8 kb fragment of ΔCDT1mero gDNA (Fig. 4.1), consistent with 
integration of the cdtABC copy downstream of the cat cassette; no hybridization to 
ΔCDT1 gDNA was observed.  A DIG-cat probe recognized 3.5 kb bands in both ΔCDT1 
and ΔCDT1mero gDNA but did not hybridize to 35000 gDNA.  These results were 
consistent with a single targeted allelic exchange at the cdtABC locus in strain ΔCDT1, as 
well as successful integration of pRAF30 (carrying wild type cdtABC) downstream of the 
cat cassette in ΔCDT1mero.  Southern blot analysis of strains ΔCDT2 and ΔCDT2rep 
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showed that ΔCDT2 yielded identical results to ΔCDT1, and ΔCDT2rep produced results 
identical to wild type strain 35000 (data not shown). 
We also tested CDT expression phenotypes of both ΔCDT1 and ΔCDT2 mutants 
and their corresponding complemented strains by probing a Western blot of whole cell 
lysates with 3 mAbs directed against each CDT subunit (Fig. 4.2).  As expected, ΔCDT1 
and ΔCDT2 lacked detectable CdtA, CdtB, or CdtC, while ΔCDT1mero and ΔCDT2rep 
express CDT subunits at levels similar to those of wild type H. ducreyi.  These results 
confirmed that expression of the three CDT subunits was ablated in the ΔCDT strains 
and restored in the analogous complemented strains.   
 
Testing virulence of H. ducreyi CDT deletion mutants in pigs. 
 CDT intoxicates a broad range of eukaryotic cells, including vascular endothelial 
cells, skin fibroblasts, and keratinocytes.  As a pathogen that infects skin, H. ducreyi 
strains secreting CDT will likely intoxicate these cell types proximal to the chancroid 
lesion, thereby contributing to local pathology.  Therefore, we hypothesized that CDT is 
important to H. ducreyi virulence and that CDT-deficient strains will accordingly be 
attenuated in models of chancroid.  To test this hypothesis we inoculated pigs either with 
wild type H. ducreyi or with mutants unable to express CDT.  We compared the survival 
of CDT-deficient strains to their wild type parent in the swine chancroid model to 
determine whether CDT expression is essential for H. ducreyi infection.   
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We inoculated pigs with wild type, CDT-deficient, or complemented H. ducreyi 
strains twice, separated by a two-week interval.  This setup allowed us two opportunities 
to assess survival of these mutants in the pig, and provided prime and boost inoculations 
for comparing elicitation of protective immunity by these strains (described later).  
Virulence of each strain was determined by counting the number of viable H. ducreyi in 
lesion biopsies 2 and 7 days post-inoculation.  Following inoculation, significantly fewer 
CFU were recovered from ΔCDT1 lesion biopsies than from 35000 lesions (Table 3), 
demonstrating that strains unable to express CDT were impaired for virulence.  However, 
neither cis-complementation (ΔCDT1mero) nor trans-complementation of the cdtABC 
mutant (ΔCDT1 pLSCDT) restored virulence.  Theorizing that strain ΔCDT1 may have 
developed a cryptic second-site mutation that was causing or augmenting its attenuated 
phenotype, we constructed a second CDT mutant, ΔCDT2.  Pigs were inoculated with 
35000, ΔCDT2, ΔCDT2 complemented with pLSCDT, or the cdtABC-repaired 
ΔCDT2rep as with the ΔCDT1 strains previously.  Again, though significantly fewer CFU 
were recovered from ΔCDT2 lesions than from 35000 lesions, complemented strains 
ΔCDT2 pLSCDT (first inoculation) and ΔCDT2rep (second inoculation) were also 
attenuated (Table 4).   
Both ΔCDT1 and ΔCDT2 were independently generated but neither could be 
complemented, suggesting that deletion of cdtABC selects for secondary attenuating 
mutations that reconstitution of cdtABC cannot recompense.  Though CDT may be an 
essential factor in H. ducreyi infection, lack of complementation prevented confirmation 
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that the virulence phenotypes of ΔCDT1 and ΔCDT2 were solely due to the absence of 
CDT.   
Beyond its potential role in contributing to chancroid-associated skin tissue 
pathology, CDT can intoxicate cells of the host immune system and thus has been 
implicated as an immunomodulatory agent.  In this manner, CDT may have additional 
effects beyond the locality of the chancroid lesion.  Repeated inoculation with H. ducreyi 
strain 35000 in the swine model has been shown to provoke only a modest humoral 
immune response (9).  The reason for the low magnitude of the anti-H. ducreyi immune 
response is not currently known.  We asserted that CDT may interfere with development 
of host immunity during H. ducreyi infection.  A repeated inoculation scheme was 
devised to test this idea; two weeks after the second inoculation of the aforementioned 
pigs, we challenged all animals with wild type H. ducreyi 35000.  We predicted that if 
CDT has a negative impact on development of host immunity to H. ducreyi, then pigs 
previously inoculated with CDT-deficient strains should be less susceptible to wild type 
(CDT+) challenge than pigs previously inoculated only with wild type 35000.  The 
number of H. ducreyi CFU recovered from each lesion biopsy was not significantly 
different, regardless of the inoculation history of the pig (Table 5).  Thus, infection with 
strains lacking CDT did not promote development of more effective anti-H. ducreyi 
immunity.     
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Toxicity of H. ducreyi CDT mutant culture supernatants in vitro. 
 To evaluate whether CDT deletion mutants produce soluble CDT activity, 
supernatants from saturated broth cultures of each mutant strain were applied to cultured 
HaCaT cells.  We evaluated the treated cells for visible signs of CDT intoxication 
(distension) and for loss of metabolic activity using the fluorescent indicator AlamarBlue.  
Supernatants derived from cdtABC deletion strains ΔCDT1 and 2 did not cause cellular 
distension of HaCaT cells even at the maximum concentration of 50 percent (Fig. 4.3).  
CDT-complemented strains (ΔCDT1mero, ΔCDT2rep) were as efficient as wild type in 
promoting distension.  Distension was concordantly accompanied by loss of metabolic 
function (Fig. 4.4).  Supernatant from ΔCDT2 pLSCDT was approximately 100-fold more 
toxic than supernatant from wild type bacteria in the metabolic assay.  Cells exposed to 
ΔCDT2 pLSCDT supernatant did not appear distended, but their nuclei were markedly 
misshapen, and few cells remained attached to the substrate (Fig. 4.3).  It is possible that 
ΔCDT2 carrying the multi-copy pLSCDT produced and secreted more CDT into the 
culture supernatant than wild type or cis-complemented strains, causing more rapid cell 
death and precluding growth-dependent distended morphology.  Cells treated with 
supernatants from ΔcdtABC::cat strains did not show an appreciable loss of viability 
compared to medium-only controls.  These results demonstrate a direct association of 
cellular distension and death with supernatants derived from strains expressing CDT, and 
a relative lack of cytotoxicity in ΔCDT culture supernatants.   
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 Because ablation of the entire cdtABC locus in H. ducreyi appears to select cryptic 
compensatory mutations resulting in attenuation, we created an H. ducreyi strain that 
expresses CDT, but whose CdtB subunit contains minimal amino acid substitutions 
abolishing deoxyribonuclease activity.  The altered “double-mutant” CdtB (dmCdtB) 
contains alanine substitutions for histidine 160 and aspartate 199 (H160A, D199A).  
These residues were chosen based on previous work showing that a similar variant of H. 
ducreyi CdtB (H160Q, D199S) was devoid of in vitro nuclease activity (39).  We created 
two H. ducreyi mutants:  DMB, which expresses the dmCdtB (H160A, D199A) in the 
context of wild type CdtA and CdtB; and WTB, a sibling of DMB in which the wild type 
version of the cdtB gene was recreated during cointegrate resolution.   
Supernatants from H. ducreyi DMB and WTB were as toxigenic as wild type in 
both distension and metabolic assays.  This result suggests that the amino acids in CdtB 
predicted to map to critical DNase I active site residues was not essential for CDT toxicity 
in this assay system, or that alanine substitution in these locations was not sufficient to 
destroy nuclease activity.   
 
In vitro nuclease activity of purified recombinant H. ducreyi CdtB variants. 
 Because strains encoding double-mutant CdtB produced active CDT in culture 
supernatants, either CdtB nuclease activity is dispensable to CDT toxicity, or the amino 
acid substitutions in our version of dmCdtB did not eliminate nuclease activity.  To 
distinguish between these possibilities, we incubated purified wild type or amino-acid-
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substituted variants of CdtB with supercoiled plasmid to assess nuclease activity in vitro.  
We expressed hexahistidine-tagged versions of CdtB, dmCdtB, and triple-mutant CdtB 
(tmCdtB; H160A, D199A, H274A) in E. coli, then purified the proteins under non-
denaturing conditions.  We incubated these recombinant proteins with supercoiled 
plasmid DNA.  Wild type CdtB and dmCdtB both displayed nuclease activity as indicated 
by the conversion of supercoiled plasmid to relaxed or linear form (Fig. 4.5).  
Furthermore, this activity was titratable (data not shown), and was not present in a 
preparation of hexahistidine-tagged LacZ purified in parallel from the same E. coli 
expression strain and vector as the CdtB variants.  Recombinant tmCdtB did not relax or 
linearize plasmid DNA (Fig. 4.5).  These results show that the two CdtB putative active 
site residues homologous to critical residues in bovine DNase I were not required for 
CdtB nuclease activity in H. ducreyi.  The lack of nuclease activity in tmCdtB may 
indicate that H274 is particularly sensitive to substitution or that the third substitution 
exceeded the threshold for substitution while maintaining activity.  Though these 
findings do not support or refute CdtB nuclease activity as the primary determinant of 
CDT toxicity, retention of nuclease activity following alteration of amino acids H160 and 
D199 is a novel finding that calls for reassessment of the functional significance of 
apparent CdtB-DNase I homology.   
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Discussion 
 
Cytolethal distending toxin has attracted a recent flurry of attention from 
researchers as a means by which pathogenic bacteria might modulate host cell activity by 
influencing the eukaryotic cell cycle.  CDT homologs have been found in a wide variety of 
gram-negative bacteria (46) including multiple pathogenic species.  Extracts of Shigella 
dysenteriae were shown to cause diarrhea and colonic epithelial damage in a CDT- and 
dose-dependent manner in a suckling mouse model (40).   E. coli O157 isolates from both 
humans and cattle express CDT (17, 33).  CDT produced by Shiga toxin-producing 
Escherichia coli (STEC) may contribute to microvascular epithelial pathology during the 
development of hemolytic uremic syndrome (29).  In a recent study in Bahrain (3), over 
80 percent of Campylobacter jejuni isolates from diarrhea victims carried the cdtB gene.  
In addition, CDT is expressed by about one-third of Actinobacillus 
actinomycetemcomitans (Aa) isolates from human patients with periodontal disease (50).  
Furthermore, supernatants from CDT-positive but not CDT-negative Aa isolates arrest 
growth of periodontal ligament cells and gingival fibroblasts in vitro; these cell types are 
both essential for healthy gum and tooth maintenance.  Although direct and 
incontrovertible association between CDT expression and clinical pathology has yet to be 
demonstrated in any pathogen, CDT clearly is a virulence factor with the potential to 
affect clinical manifestation of H. ducreyi infection.   
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Multiple studies have shown that the H. ducreyi cdtABC locus is present and 
actively expressed in 82 to 89% of H. ducreyi clinical isolates (1, 30, 42).  It is not known 
whether naturally CDT-negative strains more efficiently elicit protective immunity upon 
successive exposure, but their reduced prevalence compared to CDT-expressing isolates 
hints at a selective disadvantage.  Svensson et al. showed that recombinant H. ducreyi 
CDT expressed in E. coli inhibits the growth of human vascular endothelial cells in vitro 
(48), and propose that this inhibition slows angiogenesis and may explain the protracted 
healing process observed with chancroid ulcers.  Preliminary evidence from the swine 
chancroid model supports this hypothesis; biopsy excision sites of ΔcdtABC strains 
appear to heal markedly faster than those of CDT-expressing strains (R. A. Fulcher, 
unpublished data).  Delayed healing of chancroid lesions could increase the odds of 
transmission of H. ducreyi to other hosts, with the unfortunate corollary of increasing the 
chance of superinfection with other STI pathogens.     
The main objective of the studies described here was to determine whether CDT 
expression affects H. ducreyi virulence.  We addressed this question by comparing the 
wild type strain 35000 with a patently CDT null strain, as opposed to the cdtC mutant 
tested in the human challenge study that led to the conclusion that CDT is nonessential 
for H. ducreyi virulence (54).  We found that two independently-generated H. ducreyi 
strains lacking the entire cdtABC locus were markedly attenuated in the pig model.  
However, virulence could not be restored in either of these mutants by cis- or trans-
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complementation, suggesting that deletion of the entire cdtABC locus selected for second-
site attenuating mutation(s) that have not been identified.   
Having demonstrated that virulence attenuation associated with the ΔcdtABC 
allele cannot be complemented, we adopted a different strategy for eliminating CDT 
activity.  Because the nuclease activity of CdtB is thought to play a large (or perhaps 
singular) role in CDT toxicity, we constructed a H. ducreyi mutant intended to express a 
nuclease-negative CdtB variant with amino acids histidine 160 and aspartate 174 
exchanged for alanine.  This mutagenesis strategy was also chosen because it preserved 
the majority of the cdtABC locus, ostensibly generating less selective pressure for 
compensatory mutation.  Testing the double mutant CdtB strain would also allow us to 
determine whether the nuclease activity of CdtB is essential for H. ducreyi virulence.  Our 
findings showed, however, that culture supernatant from the double-mutant CdtB strain 
DMB intoxicated cultured cells similarly to wild type supernatant.  Although this result 
rendered DMB unsuitable as a CDT-negative strain for testing in the pig model, it 
brought into question both the essential nature of the two catalytic amino acids as well as 
the overall importance of nuclease activity in CDT toxicity.   
Structural homology between H. ducreyi CdtB and bovine DNase I active sites 
shows strong superimposition of amino acid functional groups critical for DNase I 
activity.  H. ducreyi CdtB residues His 160 and Asp 199 map to the same residues in 
bovine DNase I responsible for Mg2+ coordination and catalysis (20, 28).  H. ducreyi CdtB 
amino acids H160 and D199 have been described as essential for in vitro DNA scission 
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(39), as have the cognate residues in E. coli and C. jejuni CdtB homologs (19, 31).  Our 
studies, however, showed that H. ducreyi dmCdtB expressed in and natively purified from 
E. coli was insensitive to alanine substitution at the H160 and D199 locations; other 
studies showing loss of nuclease activity have substituted these locations with glutamine 
and serine, respectively, (31, 39).  Few examples of native CdtB purification in any 
bacterial species can be found in the literature, and preparation methods have varied 
widely to include denaturation and refolding (31, 32, 36), polymyxin B extraction (18, 
19), and using supernatants from E. coli strains expressing CdtB variants from plasmids 
(18, 19).  Because alanine substitution leaves a relatively minimal functional group 
compared to the H160Q and D199S substitutions, the fact that our dmCdtB variant has 
intact nuclease activity is confounding.  Addition of the H274A substitution appears to 
delete nuclease activity, but we do not know if this effect is dependent upon H160A 
D199A.  It also appears that single-copy expression of dmCdtB in H. ducreyi produces 
soluble CDT activity, but multi-copy expression from pLSCDTdmB in the ΔCDT2 
background does not (Fig. 4.4).  This may indicate that the alanine substitutions reduce 
the stability of dmCdtB, making it less amenable to overexpression.  Construction of an 
H. ducreyi mutant expressing triple-mutant CdtB is under way; assessment of soluble 
CDT activity from this strain may help to explore the link between CdtB nuclease activity 
and CDT toxicity.   
Overall, our results are not incongruous with the idea that CDT may be required 
for virulence in the experimental pig model of H. ducreyi infection; indeed, all CDT-
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deficient strains we tested were highly attenuated.  Without complementation analysis, 
however, it is impossible to determine whether attenuation of the CDT mutants was 
solely due to the absence of CDT.  The presumed compensatory mutations in CDT null 
strains ΔCDT1 and 2 that were not complemented by cdtABC in cis or in trans remain 
uncharacterized.  Nevertheless, attenuation of these strains in the pig model is striking, so 
the target of this alleged mutation may be an important H. ducreyi virulence determinant.  
Our next goal is to compare global gene expression between 35000 and these mutants 
using an H. ducreyi genome-wide microarray.  Ideally the gene or genes identified in this 
screen will further enlighten our understanding of the mechanism of CDT toxicity and its 
role in chancroid pathogenesis.   
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Table 4.1.  Bacterial strains and plasmids. 
Name Genotype/phenotype Source a 
   
H. ducreyi strains   
35000 wild type S. Spinola 
ΔCDT1 35000 ΔcdtABC::cat [CmR]  
ΔCDT1mero ΔCDT1 cdtABC+ merodiploid [CmR, KnR]  
ΔCDT2 second generation 35000 ΔcdtABC::cat [CmR]  
ΔCDT2rep ΔCDT2 cdtABC+ wild type locus repaired [CmS, KnS]  
WTB wt cdtB revertant from construction of 2.2  
DMB 35000 cdtB(H160A D199A)  
   
E. coli strains   
TOP10 Cloning strain; recipient for TOPO cloning Invitrogen 
BL21Star(DE3)pLysS Expression strain for pRSET plasmids [CmR] Invitrogen 
   
Plasmids   
pCR2.1-TOPO PCR cloning vector [ApR, KnR] Invitrogen 
pLS88  H. ducreyi cloning vector [KnR] (53) 
pRSM2072 Suicide vector for H. ducreyi allelic exchange; lacZ [ApR] (7) 
pRSET A E. coli N-terminal 6-His expression vector  [ApR] Invitrogen 
pLSCDT cdtABC in pLS88 [ApR] R. Heiniger 
pLSCDTdmB cdtAB(H160A D199A)C in pLS88 [ApR]  
pRAF21mat wild type mature cdtB in pRSET A [ApR]  
pRAF30 4.2-kb insert with H.d. cdtABC in pCR2.1-TOPO [ApR, 
KnR] 
 
pRAF30dmB pRAF30 cdtB(H160A D199A)[ApR, KnR]  
pRAF30tmB pRAF30 cdtB(H160A D199A H274A) [ApR, KnR]  
pRAF31 pRAF30 ΔcdtABC::cat [ApR, KnR, CmR]  
pRAF100 4.2-kb insert with H.d. cdtABC in pRSM2072 [ApR]  
pRAF100K pRAF100 with aph gene from pLS88 in Ahd I site [ApR, 
KnR] 
 
pRAF100KdmB pRAF100 cdtB(H160A D199A) [ApR, KnR]  
pRAF101 4.2-kb ΔcdtABC::cat from pRAF31 in pRSM2072 [ApR, 
CmR] 
 
pRSETdmB mature cdtB (H160A D199A) in pRSET A [ApR]  
pRSETtmB mature cdtB (H160A D199A H274A) in pRSET A [ApR]  
pRSETLacZ lacZ in pRSET A [ApR] R. Bourret 
   
a All unattributed strains and constructs were created by the author during the course of this work. 
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Table 4.2.  Oligonucleotides used in cloning, sequencing, and mutagenesis. 
Name Sequence (5' to 3') 
cdt_flank_F CATTCAGAAAAGATATTGAACAGG 
cdt_flank_R TTTCTTCGCCCCACTAAGG 
cdtB-BamHI-F a CCGGATCCATGCAATGGGTAAAGC 
cdtB-EcoRI-R GCGAATTCATTAGCGATCACGAACAAAAC 
CdtSeqF1 AATAGAAATCATGGCAGTTACTTGATAC 
CdtSeqR1 GTTATGATTTCCCATCATTTCTAATTTG 
HdOSU730F GGTATTATTAATCTGGTATTAGAGGATACG 
HdOSU730R GGATTTGATCTTCTACAATTTACGTTCC 
HdCdtB(H160A)F b GGTACTGATGTATTTTTTACAGTGGCAGCTTTGGCCACAGG 
HdCdtB(H160A)R CCTGTGGCCAAAGCTGCCACTGTAAAAAATACATCAGTACC 
HdCdtB(D199A)F GGATGGTTGTTGGTGCATTCAATCGTGCGCC 
HdCdtB(D199A)R GGCGCACGATTGAATGCACCAACAACCATCC 
HdCdtB(H274A)F 
CGCTCACAAATTACATCCGATGCATTTCCTGTTAGTTTTGT 
TCGTG 
HdCdtB(H274A)R 
CACGAACAAAACTAACAGGAAATGCATCGGATGTAATTTG 
TGAGCG 
Hd35kCDT+flank1F CGTCGGTTGTACCCAAAATCG 
Hd35kCDT+flank2F GGTGCGGTTGTCATTAAAAGTGTG 
Hd35kCDT+flank3F GCCACAGGCGGTTCTGATG 
Hd35kCDT+flank4F ACGTTAGTTCAATTTAAAGTGGTTGG 
Hd35kCDT+flank5F GTATCTCAATACGATCGATAAAGTACG 
Hd35kCDT+flank1R AATTGATGACACTAGTGACGGTG 
Hd35kCDT+flank2R TGAAGATTTAGGTGCTAAATCAGATTG 
Hd35kCDT+flank3R AAACCACACTTAACTGCTTTACCC 
Hd35kCDT+flank4R ATGCAACTTCCAGATTAGCCG 
Hd35kCDT+flank5R GCCCGTATTAGTTGGAATAAGGT 
Hd35kCDT+flank6R CGAGTCATTTGAGAAACAAGCTT 
pLS88KanF TTGGCGACCTTGCATTGCAC 
pLS88KanR CGGCGTCCAGGGAGATGTCC 
a Underlined nucleotides indicate a novel restriction site introduced for cloning. 
b Boxed nucleotides indicate mutagenesis site. 
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Table 4.5. Response of pigs challenged with H. ducreyi 35000 after previous inoculations with 
H. ducreyi ΔCDT1 derivative strains. 
 
Inoculation history a n (sites / pigs) Day 28 + 2 Day 28 + 7 
2 x 35000 38 / 6 275.2 (87.22-868.4) 153.8 (42.23-560.5) 
2 x ΔCDT1 72 / 11 305.8 (165.8-564.2) 223.0 (96.96-512.8) 
2 x ΔCDT1mero 24 / 4 139.2 (101.0-191.7) 111.0 (53.62-230.0) 
1 x ΔCDT1 pLSCDT, 
1 x ΔCDT1mero 12 / 2 228.5 (164.5-317.6) 177.4 (50.21-626.9) 
 
Values indicate H. ducreyi 35000 CFU recovered per biopsy (95% CI) as modeled by Poisson regression and GEE 
adjustment. 
a Pigs were previously inoculated at days 0 and 14 with indicated strains, then challenged with 35000 on day 28. 
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Figure 4.1.  Confirmation of CDT genotypes by Southern blot. 
Pvu I-digested genomic DNA from strains 35000 (lane 1), ΔCDT1 (lane 2), and 
ΔCDT1mero (lane 3) were probed with DIG-labeled cdtB (left panel).  The same 
membrane was stripped and reprobed with DIG-cat (right panel).  Residual cdtB signal 
remains in the cat blot due to incomplete probe removal and was used to orient the two 
images.  Marker locations were translated from measurements of the original agarose gel 
pre-transfer, and are approximate.  Image was assembled in Adobe Photoshop CS, 
maintaining identical scale between the scans of the two autoradiographs. 
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Figure 4.2.  Confirmation of H. ducreyi CDT-null mutant expression phenotypes. 
Standardized amounts of H. ducreyi 35000 (lanes marked 1, 4), ΔCDT1 (lanes 2), 
ΔCDT1mero (lanes 3), ΔCDT2 (lanes 5), and ΔCDT2rep (lanes 6) whole-cell lysate were 
resolved on SDS-PAGE and transferred to nitrocellulose, and probed with α-CdtA (1G8), 
α-CdtB (20B2), or α-CdtC (8C9) monoclonal antibodies.  Strains ΔCDT1 and ΔCDT2 
have the ΔcdtABC::cat genotype, ΔCDT1mero is a ΔcdtABC::cat cdtABC+ merodiploid, 
and ΔCDT2rep is a version of ΔCDT2 restored to wild type genotype.  Each of these two 
panels of blots was derived from a single SDS-PAGE gel, but each image was abridged 
using Adobe Photoshop CS.  The relative positions of the different Cdt species in each 
panel were preserved.   
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Figure 4.3.  Effect of H. ducreyi culture supernatants on HaCaT cell morphology. 
Chamber slides were seeded with HaCaT cells at low confluency and treated with culture 
supernatant derived from the indicated H. ducreyi strain.  After 30 hours of growth, 
HaCaT cells were fixed and stained with phalloidin (red) and DAPI (blue) to illuminate 
the overall cell structure and the cell nucleus, respectively.  Underlined supernatants were 
applied at a 1:10 dilution; others at a 1:2 dilution. 
 
Untreated 35000
∆CDT2 pLS88
(vector control) 
∆CDT2 pLSCDT
(cdtB in trans)
∆CDT2 pLSdmB
(dmcdtB in trans)
∆CDT2 35000 dmB∆CDT2rep 
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Figure 4.4.  Effect of H. ducreyi culture supernatants on HaCat cell viability in vitro. 
HaCaT cells were exposed to culture supernatants from CDT+ and CDT- strains of H. 
ducreyi in five-fold dilutions ranging from 1:2 to 1:6250.  Relative viability was measured 
using the fluorescent metabolic indicator dye AlamarBlue, comparing signal of 
supernatant-treated HaCaTs to that of untreated HaCaTs.   
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Figure 4.5.  In vitro nuclease activity of purified recombinant H. ducreyi CdtB variants. 
Recombinant hexahistidine-tagged wild type (wt), double-mutant (dm; H160A/D199A), 
and triple-mutant (tm; H160A/D199A/H274A) variants of H. ducreyi CdtB purified from 
E. coli were incubated with supercoiled pUC19 plasmid in vitro.  The resulting digest was 
resolved on agarose gel, stained with EtBr and photographed.  Nicking or double-
stranded cutting of the plasmid substrate are respectively illustrated by conversion of 
supercoiled (S) plasmid to relaxed (R) or linear (L) form.  Hexahistidine-tagged LacZ 
expressed and purified alongside the CdtB variants served as a control to ensure that E. 
coli nucleases were excluded by the nickel affinity purification process.  Buffer-only 
(buffer) and unincubated plasmid (pUC19) controls are also shown along with Invitrogen 
1kb marker (mkr).   
 
 
 
 
130 
REFERENCES 
 
 
 
1. Ahmed, H. J., L. A. Svensson, L. D. Cope, J. L. Latimer, E. J. Hansen, K. Ahlman, J. Bayat-Turk, 
D. Klamer, and T. Lagergard. 2001. Prevalence of cdtABC genes encoding cytolethal distending 
toxin among Haemophilus ducreyi and Actinobacillus actinomycetemcomitans strains. J Med 
Microbiol 50:860-4. 
2. Alfa, M. J., N. Olson, P. Degagne, F. Plummer, W. Namaara, I. Maclean, and A. R. Ronald. 
1993. Humoral immune response of humans to lipooligosaccharide and outer membrane proteins 
of Haemophilus ducreyi. J Infect Dis 167:1206-10. 
3. Al-Mahmeed, A., A. C. Senok, A. Y. Ismaeel, K. M. Bindayna, K. S. Tabbara, and G. A. Botta. 
2006. Clinical relevance of virulence genes in Campylobacter jejuni isolates in Bahrain. J Med 
Microbiol 55:839-43. 
4. Al-Tawfiq, J. A., K. L. Palmer, C. Y. Chen, J. C. Haley, B. P. Katz, A. F. Hood, and S. M. 
Spinola. 1999. Experimental infection of human volunteers with Haemophilus ducreyi does not 
confer protection against subsequent challenge. J Infect Dis 179:1283-7. 
5. Ausubel, F. A., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. 
Struhl. 1996. Current Protocols in Molecular Biology. Wiley, New York. 
6. Blackmore, C. A., K. Limpakarnjanarat, J. G. Rigau-Perez, W. L. Albritton, and J. R. 
Greenwood. 1985. An outbreak of chancroid in Orange County, California: descriptive 
epidemiology and disease-control measures. J Infect Dis 151:840-4. 
7. Bozue, J. A., L. Tarantino, and R. S. Munson, Jr. 1998. Facile construction of mutations in 
Haemophilus ducreyi using lacZ as a counter-selectable marker. FEMS Microbiol Lett 164:269-73. 
8. Cameron, D. W., J. N. Simonsen, L. J. D'Costa, A. R. Ronald, G. M. Maitha, M. N. Gakinya, M. 
Cheang, J. O. Ndinya-Achola, P. Piot, R. C. Brunham, and et al. 1989. Female to male 
transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. 
Lancet 2:403-7. 
9. Cole, L. E., K. L. Toffer, R. A. Fulcher, L. R. San Mateo, P. E. Orndorff, and T. H. Kawula. 2003. 
A humoral immune response confers protection against Haemophilus ducreyi infection. Infect 
Immun 71:6971-7. 
10. Cope, L. D., S. Lumbley, J. L. Latimer, J. Klesney-Tait, M. K. Stevens, L. S. Johnson, M. Purven, 
R. S. Munson, Jr., T. Lagergard, J. D. Radolf, and E. J. Hansen. 1997. A diffusible cytotoxin of 
Haemophilus ducreyi. Proc Natl Acad Sci U S A 94:4056-61. 
11. Cortes-Bratti, X., E. Chaves-Olarte, T. Lagergard, and M. Thelestam. 1999. The cytolethal 
distending toxin from the chancroid bacterium Haemophilus ducreyi induces cell-cycle arrest in 
the G2 phase. J Clin Invest 103:107-15. 
12. Cortes-Bratti, X., T. Frisan, and M. Thelestam. 2001. The cytolethal distending toxins induce 
DNA damage and cell cycle arrest. Toxicon 39:1729-36. 
131 
13. Deng, K., J. L. Latimer, D. A. Lewis, and E. J. Hansen. 2001. Investigation of the interaction 
among the components of the cytolethal distending toxin of Haemophilus ducreyi. Biochem 
Biophys Res Commun 285:609-15. 
14. Desjardins, M., C. E. Thompson, L. G. Filion, J. O. Ndinya-Achola, F. A. Plummer, A. R. 
Ronald, P. Piot, and D. W. Cameron. 1992. Standardization of an enzyme immunoassay for 
human antibody to Haemophilus ducreyi. J Clin Microbiol 30:2019-24. 
15. Ducrey, A. 1889. Experimentelle Untersuchungen uber den ansteckungsstof des weichen 
Schankers und uber die Bubonen. Monatsh fur Prakt Dermatol 9:387-405. 
16. Ducrey, A. 1890. Recherches expérimentales sûr la nature intaine du principe contagieux du 
chancre mou. Anal de Dermat et de Syph 3:56-57. 
17. Eklund, M., M. Bielaszewska, U. M. Nakari, H. Karch, and A. Siitonen. 2006. Molecular and 
phenotypic profiling of sorbitol-fermenting Escherichia coli O157:H- human isolates from 
Finland. Clin Microbiol Infect 12:634-41. 
18. Elwell, C., K. Chao, K. Patel, and L. Dreyfus. 2001. Escherichia coli CdtB mediates cytolethal 
distending toxin cell cycle arrest. Infect Immun 69:3418-22. 
19. Elwell, C. A., and L. A. Dreyfus. 2000. DNase I homologous residues in CdtB are critical for 
cytolethal distending toxin-mediated cell cycle arrest. Mol Microbiol 37:952-63. 
20. Evans, S. J., E. J. Shipstone, W. N. Maughan, and B. A. Connolly. 1999. Site-directed 
mutagenesis of phosphate-contacting amino acids of bovine pancreatic deoxyribonuclease I. 
Biochemistry 38:3902-9. 
21. Frisan, T., X. Cortes-Bratti, and M. Thelestam. 2002. Cytolethal distending toxins and activation 
of DNA damage-dependent checkpoint responses. Int J Med Microbiol 291:495-9. 
22. Frisk, A., H. J. Ahmed, E. Van Dyck, and T. Lagergard. 1998. Antibodies specific to surface 
antigens are not effective in complement-mediated killing of Haemophilus ducreyi. Microb Pathog 
25:67-75. 
23. Frisk, A., M. Lebens, C. Johansson, H. Ahmed, L. Svensson, K. Ahlman, and T. Lagergard. 
2001. The role of different protein components from the Haemophilus ducreyi cytolethal 
distending toxin in the generation of cell toxicity. Microb Pathog 30:313-24. 
24. Haghjoo, E., and J. E. Galan. 2004. Salmonella typhi encodes a functional cytolethal distending 
toxin that is delivered into host cells by a bacterial-internalization pathway. Proc Natl Acad Sci U S 
A 101:4614-9. 
25. Hammond, G. W., M. Slutchuk, J. Scatliff, E. Sherman, J. C. Wilt, and A. R. Ronald. 1980. 
Epidemiologic, clinical, laboratory, and therapeutic features of an urban outbreak of chancroid in 
North America. Rev Infect Dis 2:867-79. 
26. Hobbs, M. M., L. R. San Mateo, P. E. Orndorff, G. Almond, and T. H. Kawula. 1995. Swine 
model of Haemophilus ducreyi infection. Infect Immun 63:3094-100. 
27. Jessamine, P. G., and A. R. Ronald. 1990. Chancroid and the role of genital ulcer disease in the 
spread of human retroviruses. Med Clin North Am 74:1417-31. 
132 
28. Jones, S. J., A. F. Worrall, and B. A. Connolly. 1996. Site-directed mutagenesis of the catalytic 
residues of bovine pancreatic deoxyribonuclease I. J Mol Biol 264:1154-63. 
29. Karch, H., A. W. Friedrich, A. Gerber, L. B. Zimmerhackl, M. A. Schmidt, and M. 
Bielaszewska. 2006. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. 
Semin Thromb Hemost 32:105-12. 
30. Kulkarni, K., D. A. Lewis, and C. A. Ison. 2003. Expression of the cytolethal distending toxin in a 
geographically diverse collection of Haemophilus ducreyi clinical isolates. Sex Transm Infect 
79:294-7. 
31. Lara-Tejero, M., and J. E. Galan. 2000. A bacterial toxin that controls cell cycle progression as a 
deoxyribonuclease I-like protein. Science 290:354-7. 
32. Lara-Tejero, M., and J. E. Galan. 2001. CdtA, CdtB, and CdtC form a tripartite complex that is 
required for cytolethal distending toxin activity. Infect Immun 69:4358-65. 
33. Lee, J. H., and S. J. Choi. 2006. Isolation and characteristics of sorbitol-fermenting Escherichia 
coli O157 strains from cattle. Microbes Infect 8:2021-6. 
34. Lewis, D. A., M. K. Stevens, J. L. Latimer, C. K. Ward, K. Deng, R. Blick, S. R. Lumbley, C. A. 
Ison, and E. J. Hansen. 2001. Characterization of Haemophilus ducreyi cdtA, cdtB, and cdtC 
mutants in in vitro and in vivo systems. Infect Immun 69:5626-34. 
35. Li, L., A. Sharipo, E. Chaves-Olarte, M. G. Masucci, V. Levitsky, M. Thelestam, and T. Frisan. 
2002. The Haemophilus ducreyi cytolethal distending toxin activates sensors of DNA damage and 
repair complexes in proliferating and non-proliferating cells. Cell Microbiol 4:87-99. 
36. Mao, X., and J. M. DiRienzo. 2002. Functional studies of the recombinant subunits of a cytolethal 
distending holotoxin. Cell Microbiol 4:245-55. 
37. Morse, S. A. 1989. Chancroid and Haemophilus ducreyi. Clin Microbiol Rev 2:137-57. 
38. Museyi, K., E. Van Dyck, T. Vervoort, D. Taylor, C. Hoge, and P. Piot. 1988. Use of an enzyme 
immunoassay to detect serum IgG antibodies to Haemophilus ducreyi. J Infect Dis 157:1039-43. 
39. Nesic, D., Y. Hsu, and C. E. Stebbins. 2004. Assembly and function of a bacterial genotoxin. 
Nature 429:429-33. 
40. Okuda, J., M. Fukumoto, Y. Takeda, and M. Nishibuchi. 1997. Examination of diarrheagenicity 
of cytolethal distending toxin: suckling mouse response to the products of the cdtABC genes of 
Shigella dysenteriae. Infect Immun 65:428-33. 
41. Plummer, F. A., J. N. Simonsen, D. W. Cameron, J. O. Ndinya-Achola, J. K. Kreiss, M. N. 
Gakinya, P. Waiyaki, M. Cheang, P. Piot, A. R. Ronald, and et al. 1991. Cofactors in male-
female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 163:233-9. 
42. Purven, M., E. Falsen, and T. Lagergard. 1995. Cytotoxin production in 100 strains of 
Haemophilus ducreyi from different geographic locations. FEMS Microbiol Lett 129:221-4. 
43. Shenker, B. J., D. Besack, T. McKay, L. Pankoski, A. Zekavat, and D. R. Demuth. 2004. 
Actinobacillus actinomycetemcomitans cytolethal distending toxin (Cdt): evidence that the 
holotoxin is composed of three subunits: CdtA, CdtB, and CdtC. J Immunol 172:410-7. 
133 
44. Shenker, B. J., R. H. Hoffmaster, T. L. McKay, and D. R. Demuth. 2000. Expression of the 
cytolethal distending toxin (Cdt) operon in Actinobacillus actinomycetemcomitans: evidence that 
the CdtB protein is responsible for G2 arrest of the cell cycle in human T cells. J Immunol 
165:2612-8. 
45. Shenker, B. J., T. McKay, S. Datar, M. Miller, R. Chowhan, and D. Demuth. 1999. 
Actinobacillus actinomycetemcomitans immunosuppressive protein is a member of the family of 
cytolethal distending toxins capable of causing a G2 arrest in human T cells. J Immunol 162:4773-
80. 
46. Smith, J. L., and D. O. Bayles. 2006. The contribution of cytolethal distending toxin to bacterial 
pathogenesis. Crit Rev Microbiol 32:227-48. 
47. Stevens, M. K., J. L. Latimer, S. R. Lumbley, C. K. Ward, L. D. Cope, T. Lagergard, and E. J. 
Hansen. 1999. Characterization of a Haemophilus ducreyi mutant deficient in expression of 
cytolethal distending toxin. Infect Immun 67:3900-8. 
48. Svensson, L. A., P. Henning, and T. Lagergard. 2002. The cytolethal distending toxin of 
Haemophilus ducreyi inhibits endothelial cell proliferation. Infect Immun 70:2665-9. 
49. Svensson, L. A., A. Tarkowski, M. Thelestam, and T. Lagergard. 2001. The impact of 
Haemophilus ducreyi cytolethal distending toxin on cells involved in immune response. Microb 
Pathog 30:157-66. 
50. Tan, K. S., K. P. Song, and G. Ong. 2002. Cytolethal distending toxin of Actinobacillus 
actinomycetemcomitans. Occurrence and association with periodontal disease. J Periodontal Res 
37:268-72. 
51. Thomas, C. E., N. H. Carbonetti, and P. F. Sparling. 1996. Pseudo-transposition of a Tn5 
derivative in Neisseria gonorrhoeae. FEMS Microbiol Lett 145:371-6. 
52. Wasserheit, J. N. 1992. Epidemiological synergy:  interrelationships between human 
immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 19:61-
77. 
53. Willson, P. J., W. L. Albritton, L. Slaney, and J. K. Setlow. 1989. Characterization of a multiple 
antibiotic resistance plasmid from Haemophilus ducreyi. Antimicrob Agents Chemother 33:1627-
30. 
54. Young, R. S., K. R. Fortney, V. Gelfanova, C. L. Phillips, B. P. Katz, A. F. Hood, J. L. Latimer, 
R. S. Munson, Jr., E. J. Hansen, and S. M. Spinola. 2001. Expression of cytolethal distending 
toxin and hemolysin is not required for pustule formation by Haemophilus ducreyi in human 
volunteers. Infect Immun 69:1938-42. 
 
CHAPTER 5 
 
DISCUSSION 
 
 
 Up until the 1980s and 90s, chancroid was a highly prevalent genital ulcer disease in 
developing nations.  In South Africa, chancroid accounted for up to 50% of GUD cases in 
men as recently as 1985, outnumbering cases of syphilis (Treponema pallidum), granuloma 
inguinale (Calymmatobacterium granulomatis), lymphogranuloma venereum (Chlamydia 
trachomatis), and herpes simplex virus (20).  In many locations over the past few years, 
however, chancroid incidence has steadily declined.  In the United States, where nearly 5000 
cases of chancroid occurred in 1987, only 17 cases of chancroid were reported in 2005, which 
is the lowest number ever reported (7).  Even in some areas of Africa where chancroid is 
much more prevalent than in the U. S. and Europe, clinicians have reported a distinct 
downward trend in the incidence of chancroid (22), with up to a 25-fold decrease between 
1993 and 2003 in some cases (26).  Many factors have probably contributed to this apparent 
recession of chancroid.  More effective prevention strategies, including emphasis on genital 
hygiene, encouragement of condom use and simple instruction to abstain from intercourse 
when genital ulcers are present (on self or partner) have likely played a role in this reduction 
in frequency (29).   
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Although antibiotic-resistant isolates are commonly seen in some communities, there 
are still several viable and effective options for antimicrobial therapy against Haemophilus 
ducreyi.  First-line therapies such as azithromycin and ceftriaxone can resolve chancroid with 
a single dose, eliminating low patient compliance as an obstacle to successful treatment or a 
source of further development of antibiotic-resistant isolates (40).  Single-dose azithromycin 
treatment is particularly effective (36) and may render individuals refractory to reinfection 
with H. ducreyi for nearly two months (34).  Access to modern health care unfortunately still 
presents a problem for many areas with endemic chancroid, so these often-expensive 
therapies are not widely available in the places most burdened with this disease (35). 
 Chancroid is not a lethal disease.  Lesions remain localized to the skin and H. ducreyi 
has never been shown to cause systemic infection.  Still, chancroid lesions are painful, 
potentially disfiguring, and subject their bearer to increased risk of acquiring other STI 
pathogens (35).  Though susceptible to antibiotic therapy, H. ducreyi aggressively damages 
host skin both by manufacturing toxins as well as attracting a concentrated locus of host-
generated inflammation.  The effects of these bacterial toxins and components may remain 
within chancroid ulcers even after clearance of H. ducreyi, and immunocompromised 
individuals suffer more intense, slower-healing lesions that respond poorly to drug therapy 
(37, 38).  Further understanding the mechanisms by which H. ducreyi mediates cutaneous 
damage may lead to the development of agents that enhance antimicrobial therapy by halting 
progression of ulcerative damage or speeding the resolution of ulcers in patients at risk for 
protracted chancroid pathology.  Any strategies that reduce the length of time that chancroid 
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lesions remain a cofactor for STI acquisition and transmission could have a positive impact 
on global public health. 
 It is important to consider that humans are the sole vectors and victims of 
Haemophilus ducreyi; therefore, should the incidence of chancroid be suppressed to a 
sufficiently low state, eradication could be attainable.  However, antibiotic treatment alone 
may not be sufficient to attain this goal, even excluding the possibility of resistance to new 
classes of antibiotics, for several reasons.  H. ducreyi infection does not promote protection 
upon subsequent exposure, making antibiotic treatment effective for only a single instance of 
chancroid in a given individual.  Upon re-exposure, patients require re-treatment.  Areas 
where public health infrastructure is poor and where the commercial sex trade is widespread 
are fertile ground for endemic chancroid.  Some researchers have even suggested that 
chancroid is a bellwether disease indicating communities whose social structure and policies 
are strongly imbalanced or ill-equipped to deal with endemic STI (29).  Even in the face of 
the overall downward trend, the highly infectious nature of H. ducreyi and the episodic 
nature of chancroid outbreaks (for example, the U. S. experienced a surge from < 1000 to 
between 2000 and 5000 cases/year between 1983 and 1995) suggest that resurgence may be a 
likely event (7). 
 An effective immunization against H. ducreyi infection is the best strategy for 
eliminating chancroid.  A single or few administrations of such a vaccine would render 
individuals refractory to acquisition or transmission of H. ducreyi for an extended period of 
time.  Some common sexually-transmitted pathogens have evolved mechanisms of evading 
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immunity:  Neisseria gonorrhoeae varies the antigenic character or expression state of its 
exposed surface proteins (21), and HIV rapidly develops resistance to antiviral compounds 
due to the high mutation rate of its replicative reverse transcriptase (24).  These mechanisms 
mean that for these pathogens, any vaccine may ultimately be “outgrown” by the evolution of 
strains that circumvent its protective effect.  Even with the advent of the whole-genome 
sequence of H. ducreyi, no evidence for systems of antigenic variation or hypermutation have 
been detected.  Furthermore, at least six surface-exposed proteins in H. ducreyi are important 
or essential in experimental models of chancroid: DltA, DsrA, Flp, HgbA, NcaA, and Pal (2, 
6, 16, 17, 19, 28).  For these reasons, we submit that H. ducreyi may be a suitable target for 
vaccine design.  The studies presented in this dissertation have attempted to gain insight into 
the means by which H. ducreyi causes disease, with the ultimate goal of generating effective 
strategies for defeating chancroid.   
 
Evaluating the humoral immune response to Haemophilus ducreyi. 
 The studies presented in Chapter 2 investigated the extent of H. ducreyi evasion of the 
humoral immune response in the pig model of chancroid and found that repeated 
inoculation with a wild type H. ducreyi isolate does promote formation of modest but 
passively transferable humoral response.  Although some studies of individuals with natural 
chancroid indicated that H. ducreyi serum antibodies are produced over prolonged ulcerative 
infection, these antibodies do not effectively fix complement to kill H. ducreyi in vitro.  It is 
also improbable to locate and observe chancroid patients who have been iteratively infected 
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with the same strain to see if a homologous prime-and-boost produces a more effective 
response.  The human challenge model of chancroid addressed this question by 
experimentally infecting volunteers twice with strain 35000, but showed that there was no 
significant increase in specific antibody titer after two experimental infections of 3 to 7 day 
duration spaced 5 to 17 months apart (3).  Experimental lesions in this model cannot 
progress past the pustular stage because of the painful nature of ulceration.  The abridged 
course of infection as well as the limited number of inoculations may have prevented 
development of a more profound immune response.    
In the pig model, we inoculated animals up to four times successively and allowed 
lesions to develop for up to a week, at which stage overt ulcers had formed.  With each round 
of inoculation, we saw a successive reduction in the number of bacteria recovered from each 
lesion with a concordant reduction in the histopathological lesion severity.  This mitigation 
of disease symptoms was accompanied by a five-fold increase in specific serum IgG.  Naïve 
pigs infused with immune serum then challenged with wild type H. ducreyi had intralesion 
bacterial recovery and histopathology scores similar to those of a multiply-infected pigs, and 
not preimmune pigs.  Though the magnitude of this immune response was not large and the 
protection afforded by passive immunization cannot be deemed complete, this finding 
revealed the important fact that an antibody response is appropriate and effective against H. 
ducreyi infection.  It follows that an artificially amplified immune response may produce a 
consonantly amplified level of protection. 
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Elkins et al. recently reported protection against experimental H. ducreyi challenge by 
vaccination in the pig model (1).  Hemoglobin binding protein A (HgbA), a highly-conserved 
surface protein involved in iron acquisition by H. ducreyi (12, 13, 15, 30) and essential for its 
survival in the human host (2), was purified and used to immunize pigs.  Compared to mock-
vaccinated animals, lesion severity was dramatically reduced and recovery of H. ducreyi was 
nil.  The antibody response induced by HgbA vaccination was specific, robust, bactericidal, 
and prevented the proper function of HgbA as an iron acquisition system, thus 
demonstrating the efficacy of a well-targeted, high-magnitude immune response against H. 
ducreyi challenge.   
 
Identification of NcaA:  an essential virulence factor and potential immunogen. 
 In Chapter 3, we detailed the characterization of NcaA, H. ducreyi outer membrane 
protein with homology to DsrA, an H. ducreyi OMP that provides resistance to killing by 
serum complement and is essential for both swine and human experimental infection (6, 8, 
14).  The predicted structures of NcaA and DsrA classify them as Oca proteins, which are 
found in several gram-negative bacteria including Yersinia, Escherichia, and Moraxella 
species, and are generally involved in adherence to extracellular matrix proteins within host 
tissue (27).  Our results showed that, like DsrA, NcaA is one of the OMP antigens recognized 
by H. ducreyi-immune pig serum; discordantly, NcaA was not shown to be involved in serum 
resistance.  We showed that NcaA specifically mediates binding to type I collagen, the 
predominant structural protein found in human skin, and H. ducreyi has been found 
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associated with collagen in both natural (5) and experimentally-induced (4) human 
chancroid lesions.  Though we have not directly linked NcaA-mediated collagen binding to 
virulence, we showed that NcaA is indispensable for infection in both swine and human 
models of chancroid.   
As a multifunctional H. ducreyi OMP that is essential to virulence, we submit that 
NcaA, much like HgbA, is a promising vaccinogen candidate.  We have begun immunization 
studies to this effect in the pig model, but the oligomeric nature of NcaA has presented 
technical difficulties in expressing and purifying sufficient recombinant NcaA for 
immunization.  Also we have been unable to assess the efficiency with which anti-NcaA 
antibodies are bactericidal.  One potential complication with using NcaA as a vaccine subunit 
is that NcaA shows a modest amount of antigenic heterogeneity across “Class I” and “Class 
II” H. ducreyi species (39).  This problem could be overcome by immunization with a 
multivalent NcaA preparation.  Further, as an Oca family member, NcaA immunization 
could conceivably afford the benefit of cross-reactive immunity to other Oca-expressing 
pathogens.  
 
Assessing the effects of CDT on H. ducreyi pathogenesis and host immunity. 
 The studies outlined in Chapters 2 and 3 addressed the presence and efficacy of an 
anti-H. ducreyi humoral response and the discovery of an H. ducreyi OMP that is essential to 
virulence and a promising vaccine target.  Studies outlined in Chapter 4 were intended to 
explore a potential cause of the diminished immunity seen in natural H. ducreyi infection.  H. 
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ducreyi cytolethal distending toxin (CDT) intoxicates a broad range of eukaryotic cell types 
present in both the skin (keratinocytes, skin fibroblasts) as well as involved in the immune 
response (dendritic cells, macrophages, lymphocytes) (9-11, 18, 23, 31, 32).  For these 
reasons, respectively, we proposed that CDT may influence the ability of H. ducreyi to infect 
the skin as well as to affect adaptive immunity and the development of a protective humoral 
response.  Two ΔCDT (cdtABC locus deletion) mutants created in parental strain H. ducreyi 
35000 were profoundly attenuated in the pig model of chancroid.  However, addition of the 
cdtABC locus in cis or in trans to either of these mutant strains did not restore virulence.  We 
also designed a consecutive prime-and-boost inoculation experiment to determine whether 
repeated administration of CDT-deficient H. ducreyi enhanced immunity to wild type 
challenge.  Pigs challenged with 35000 following either two inoculations of 35000 or two 
inoculations of ΔCDT1 were equally permissive to wild type infection.   
Though we cannot discount the importance of CDT in H. ducreyi infection, lack of 
complementation suggests that deletion of the cdtABC locus selects for compensatory 
mutations that impart an attenuated phenotype.  The fractional contributions of cdtABC and 
the other currently unidentified gene(s) to chancroid pathology, therefore, cannot be 
ascertained.  It may be possible to locate these secondary mutations and independently 
measure their contribution to virulence.  The effect of H. ducreyi CDT on the adaptive 
immune response is also questionable because the cryptic attenuation of the ΔCDT strains 
may impair their growth in vivo such that their numbers are insufficient to immunize their 
host.  In light of these data, we can neither prove nor disprove our prediction that a truly 
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isogenic cdtABC mutant will be more immunogenic than wild type.  We will continue to 
investigate this hypothesis in future experiments.  The concluding text describes our first 
effort to that effect. 
In an attempt to ablate CDT function without removing the entire locus (and 
theoretically avoiding compensatory mutation), we constructed an H. ducreyi mutant 
expressing a modified “double mutant” CdtB (dmCdtB).  This mutant was intended to lack 
DNase activity, with the two amino acid substitutions mapping to the putative nuclease active 
site of CdtB (25).  We found that supernatants from H. ducreyi DMB (35000 dmcdtB) are as 
toxigenic as wild type to cultured cells and that in vitro nuclease activity of recombinant 
dmCdtB is intact.  Therefore the third attempt to create an isogenic mutant deficient in CDT 
activity failed.  These findings were surprising because a number of studies demonstrated 
ablation of the same putatively catalytic amino acids in CdtB results in loss of nuclease 
function (25, 33).  Our effort to produce H. ducreyi strain DMB is unique; all published 
studies thus far have used purified recombinant CdtB variants instead of isogenic mutants 
within the native organism.  We also chose to make more aggressive amino acid substitutions 
than other researchers (our H160A, D199A as opposed to H160Q, D199S).  Both of these 
factors may explain the persistence of nuclease activity in our strain DMB and  recombinant 
dmCdtB preparations as opposed to other researchers’ findings.   
 In adding a third substitution, H274A, to create the recombinant (“triple mutant”) 
tmCdtB, we appear to have eliminated in vitro nuclease activity.  We plan to introduce this 
cdtB allele into H. ducreyi.  If culture supernatants derived from this strain are devoid of or 
143 
highly diminished in CDT toxicity, we will repeat our initial experiments in the swine model 
to ascertain the contribution of CDT to H. ducreyi pathogenesis.   
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